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 1 
Abstract 
 
 
 
ABSTRACT 
In present investigation an attempt has been made to design and develop some 
Gliclazide  matrix  tablets using Hydroxy propyl cellulose, Hydroxy propyl methyl 
cellulose  and  their  combination  as  release  retarding  polymers.  Gliclazide  is  oral 
hypoglycaemic  drug  which  lowers  blood  glucose  level  and  has  been  selected  to 
prepare sustained release dosage forms. 
Gliclazide sustained release matrix tablets were prepared using Hydorxy Propyl 
Cellulose, Hydroxy Propyl Methyl Cellulose and their combination as base polymer 
by wet granulation method. FT-IR spectral analysis showed that characteristic peak of 
Gliclazide pure drug was retained in the spectra of all the formulations indicating the 
inactness of the drug in all the formulations. The prepared tablets were evaluated for 
number of parameters like thickness, diameter, weight variation, swelling index and in 
vitro release studies. All the prepared tablets were of smooth surface and  elegant 
texture. The tablets prepared were checked visually for its appearance & surface 
texture. The weights of the tablets were in the range of 250 ± 5 mg. The thickness of 
the tablet was in the range of 4.45 ± 0.11 mm to 4.51 ± 0.12 mm 
Gliclazide matrix tablets formulated employing HPMC K-4M and 
combination of HPMC K-4M and HPC 75-100 provided slow and controlled release 
of Gliclazide up to 12 hr. 
Drug release from the matrix tablets formulation containing HPMC K-4M and HPC 
 
75-100 follows first order drug release with non-fickian diffusion. 
All the tablet formulation showed compliance with pharmacopoeial standard. 
As  the  time  increases,  the  swelling  index  was  increased;  later  on  it  decreases  
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Gradually due to dissolution of outermost –gelled layer of tablet into 
dissolution medium. Comparison between HPMC K-4M,  HPC 75-100 and their 
combination it has  been  observed  that  swelling  index  of  HPMC  K-4M  was  
significantly  more  compared to HPC 75-100. Whereas swelling index in case of 
HPC 75-100 is less as compare to HPMC K-4M and HPC 75-100 combination. The 
dissolution result shows that an increased amount of polymer resulted in reduced drug 
release. A concentration dependent drug release is evident in case of the polymer 
i.e., lower concentration of polymers, release is marginally retarded at higher 
concentration is considerable. 
Prepared matrix formulation containing HPMC K-4M (F6 ), HPMC K-4M and 
 
HPC 75-100 combination (F9 ) probably showing better release based up to 98 % to 99 
 
% drug release within 12 hour. 
 
 
 
 
Key words: sustained release, HPMC K-4M, HPC 75-100. 
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µg : micro gram 
 
0C : Degree centigrade 
 
CDR : Cumulative Drug Released. 
 
Conc. : Concentration. 
 
t50% 
 
t90% 
: Time of release of 50% of drug 
 
: Time of release of 90% of drug 
 
F : Formulation 
 
HPMC : Hydroxy Propyl MethylCellulose 
 
HPC : Hydroxy Propyl Cellulose 
 
GIT : Gastrointestinal tract 
 
Hrs. : Hours 
 
I.R : Infra red. 
mm : millimeter 
nm : Nanometer 
RPM : Revolution per Minute 
 
SR : Sustained Release 
 
UV : Ultra violet 
 
HPLC : High Performance Liquid Chromatography 
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Chapter- I Introduction 
 
 
I. INDRODUCTION 
Pharmaceutical products designed for oral delivery are mainly immediate 
release type or conventional drug delivery systems, which are designed for immediate 
release of drug for rapid  absorption. These immediate release dosage forms have 
some limitations such as. 
1)  Drugs with short half-life requires frequent administration, which increases 
chances of missing dose of drug leading to poor patient compliance. 
2)  A typical peak-valley plasma concentration-time profile is obtained which 
makes attainment of steady state condition difficult. 
3)  The unavoidable fluctuations in the drug concentration may lead to under 
 
medication or  overmedication  as  the  CSS values  fall  or  rise  beyond  the 
 
Therapeutic range. 
 
4)  The  fluctuating  drug  levels  may  lead  to  precipitation  of  adverse  effects 
especially of a  drug with small therapeutic index, whenever overmedication 
occurs. 1,2of therapeutic benefits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. No: 1- A hypothetical plasma concentration-time profile from conventional 
multiple dosing and single doses of sustained and controlled delivery 
formulations. 
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In order to overcome the drawbacks of conventional drug delivery systems, 
several  technical  advancements  have  led  to  the  development  of  controlled  drug 
delivery system that could revolutionize method of medication and provide a number 
             Of  therapeutics benefits. 
 
 
 
Sustained Release: 
Sustained release tablet allowing a twofold or greater reduction in frequency 
of   administration  of  a  drug  in  comparison  with  the  frequency  required  by  a 
conventional dosage form. It is designed to maintain constant levels of a drug in the 
patient's bloodstream by releasing  the  drug over an extended period. Maintaining 
constant  blood  levels  of  the  drug  in  the  bloodstream  increases  the  therapeutic 
effectiveness of the drug 3 
 
Advantages of sustained release formulations:- 
 
1.  Enhance patient compliance and convenience. 
 
2.  Reduction in dosing frequency. 
 
3.  Reduced fluctuations in circulating drug levels. 
 
4.  More uniform effect. 
 
5.  Employ less total drug that, 
 
a) Minimize or eliminates local side effects. 
 
b) Minimize or eliminates systemic side effects. 
 
c) Minimize drug accumulation with chronic dosing. 
 
d) Obtains less potentiation or reduction in drug activity on chronic use. 
 
 
6. Safety margin of potent drug is increased by technically excellent designing of 
formulation.
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7. Improve efficiency in treatment –by 
 
a) Cure or control of condition. 
b) Improve or control condition. 
c) Make use of specific effect. 
Eg.SR Aspirin for morning relief of arthritis 
d) Improve bioavailability of some drugs. 
8. Patient care time is reduced. 
 
9. Night time dosing can be avoided for patient convenience 
 
          10. Product life time is increased in sustained release formulations. Particles 
of drug are coated with matrix or entire product is matrix coated which along with its 
main  function  of   sustained  action,  avoid  exposure  of  unstable  drug  to  the 
environment and render it stable. 4 
 
Disadvantages of sustained release formulations: 
 
1. If there requires immediate change during the therapy or if any significant 
adverse effect  is  noted and prompt termination of therapy is needed, Sustained 
release does not permit immediate termination of therapy. 
2. More costly process and equipment are needed in manufacturing of SRDF‘s. 
3. Physician has less flexibility in adjusting dosage regimen as this is fixed by 
design of dosage form. 
 
 
4. Risk of dose dumping, usually SRDF’s contain drug amount that is 3-4 times 
more than conventional formulations. Sometimes this large quantity of drug may 
get rapidly released leading to toxicity. 
5. Reduced drug absorption may delay onset of action. The effect of food on drug 
absorption kinetics may differ markedly from one SR formulations to another.
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6. Drug absorbed at specific time in GIT cannot be formulated in SRDFs 
 
7. Increased potential for first pass clearance. 
 
8. For  oral  SRDF  effective  drug  release  is  influenced  and  limited  by  GI 
 
Residence time. 
 
9. SRDF’s are designed for normal population that is on the basis of the 
biological half lives. Since disease state that alters drug dispositions as well as 
interpatient variability in pharmacokinetics parameters are not accommodated. 
10.Drugs  which  are  acted  upon  by  enzymes  in  intestine  undergo  significant 
enzymatic breakdown as drug remains in body for longer time. 
11.In case of accidental failure of the product effective antidote may be difficult 
 
to employ. 4 
 
1.2 Classification of sustained release drug delivery system: 
 
Considering  the  mechanism  of  controlling  the  drug  release  the  system  is 
classified as follows:- 
1.  Chemically controlled systems 
a.   Biodegradable system 
b. Drug polymer conjugates 
2.  Diffusion controlled systems 
a.   Matrix diffusion 
b.  Polymer erosion 
c.   Polymer swelling 
d.  Geometry 5 
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A Useful Classification based on drug release from the SRDF is as follows:- 
 
A. continuous release systems:- 
These systems release the drug continuously for prolonged period of time 
along the entire length of GIT with normal transit time. 6 
 
Different systems under this class are – 
 
1.  Dissolution controlled release systems 
 
2.  Diffusion controlled release systems 
 
3.  Dissolution and diffusion controlled release systems 
 
4.  Ion exchange resin drug complex 
 
5.  Slow dissolving salts and complexes 
 
6.  pH dependent formulations 
 
7.  Osmotic pressure controlled systems 
 
8.  Hydrodynamic pressure controlled systems 
 
B. Delayed transit and continuous release systems:- 
 
These  systems  are  designed  to  prolong  release  of  drug  with  increased 
residence time  in GIT. Such dosage forms are designed to remain in the stomach. 
Therefore the drug presented in such systems should be stable at gastric pH. This 
class includes following systems 7 
 
1.  Altered density systems 
 
2.  Mucoadhesive systems 
 
3.  Size based systems 
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C. Delayed release systems:- 
 
These systems are fabricated to release the drug only at specific site in the 
 
GIT. The drugs those are 7 
 
a.   Destroyed in stomach or by intestinal enzymes 
 
b.   Kn o wn  to cause gastric irritation 
 
c.   Absorbed from specific site in intestine, or exert local effect at specific GI site 
are formulated in such systems. 
The two types of delayed release systems are:- 
 
1.  Intestinal release systems 
 
2.  Colonic release systems 
 
 
Oral Controlled Drug Delivery Systems7: 
 
 
Oral controlled release drug delivery is a drug delivery system that provides 
the  continuous oral delivery of drugs at predictable and reproducible kinetics for a 
predetermined period  throughout the course of GI transit and also the system that 
target the delivery of a drug to a specific region within the GI tract for either a local or 
systemic action. 
 
 
All the pharmaceutical products formulated for systemic delivery via the oral 
route of administration, irrespective of the mode of delivery (immediate, sustained or 
controlled release) and the design of dosage form (either solid dispersion or liquid), 
must be developed within the intrinsic characteristics of GI physiology. Therefore the 
scientific framework required for the successful  development of oral drug delivery 
systems consists of basic understanding of (i) physicochemical, pharmacokinetic and 
pharmacodynamic  characteristics  of  the  drug  (ii)  the  anatomic  and  physiologic 
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characteristics of the gastrointestinal tract and (iii) physicochemical characteristics 
and the drug delivery mode of the dosage form to be designed. 
 
The main areas of potential challenge in the development of oral controlled drug 
delivery systems are:- 
1)  Development of a drug delivery system: To develop a viable oral controlled 
release drug delivery system capable of delivering a drug at a therapeutically 
effective rate to a desirable site for duration required for optimal treatment. 
2)  Modulation of gastrointestinal transit time: To modulate the GI transit time so 
that the drug delivery system developed can be transported to a target site or to 
the vicinity of an  absorption  site and reside there for a prolonged period of 
time to maximize the delivery of a drug dose. 
3)  Minimization of hepatic first pass elimination: If the drug to be delivered is 
subjected  to  extensive  hepatic  first-pass  elimination,  preventive  measures 
should be devised to either bypass or minimize the extent of hepatic metabolic 
effect. 
 
Methods used to achieve controlled release of orally administered drugs.8 
 
A. Diffusion Controlled System: 
 
Basically diffusion process shows the movement of drug molecules from a 
region of a higher concentration to one of lower concentration. This system is of two 
types: 
a) Reservoir type: 
A core of drug surrounded by polymer membrane, which controls the release 
rate, characterizes reservoir devices. 
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Advantages: 
 
Zero order delivery is possible; release rate varies with polymer type. 
 
Disadvantages: 
 
1)  System must be physically removed from implant sites. 
 
2)  Difficult to deliver high molecular weight compounds. 
 
3)  Increased cost per dosage unit, potential toxicity if system fails. 
 
Ficks first law of diffusion describes the diffusion process. 
 
J= - D dc/dx. 
 
D = diffusion coefficient in area/ time 
 
      dc/dx = change of concentration 'c' with distance 'x 
 
b) Matrix type: 
 
Matrix system is characterized by a homogenous dispersion of solid drug in a 
polymer mixture. 
Advantages: 
 
Easier to produce than reservoir or encapsulated devices, can deliver high 
molecular weight compounds. 
Disadvantages: 
 
Cannot provide zero order release, removal of remaining matrix is necessary 
for implanted system. 
Higuchi  has  derived  the  appropriate  equation  for  drug  release  from  this 
system, 
M = K t½ 
M = amount of drug released per unit area, 
K = Constant 
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B. Dissolution Controlled Systems: 
 
a) Reservoir type:Drug is coated with a given thickness coating, which is slowly 
dissolved in the contents of gastrointestinal tract. By alternating layers of drug with 
the rate controlling coats as shown in figure no.2, a pulsed delivery can be achieved. 
If the outer layer is quickly releasing bolus dose of the drug, initial levels of the drug 
in the body can be quickly established with pulsed intervals. 
 
 
Fig.No.2: Schematic representation of diffusion controlled drug release reservoir 
system. 
b) Matrix  type: 
 
The more common type of dissolution controlled dosage form as shown in 
figure no.3. It can be either a drug impregnated sphere or a drug impregnated tablet, 
which will be subjected to slow erosion. 
 
Fig.No.3: Schematic representation of diffusion controlled drug release matrix 
system. 
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C. Bioerodible and Combination of Diffusion and Dissolution Systems: 
 
It is characterized by a homogeneous dispersion of drug in an erodible matrix. 
 
 
 
 
Fig.No.4:   Drug   delivery   from   (a)   bulk-eroding   and (b)   surface-eroding 
 
Bioerodible systems. 
 
Advantages: 
 
• All the advantages of matrix dissolution system. 
 
• Removal from implant site is not necessary. 
 
Disadvantages: 
 
• Difficulty to control kinetics owing to multiple processes of release. 
 
• Potential toxicity of degraded polymer must be considered. 
 
D. Methods using Ion Exchange: 
It is based on the drug resin complex formation when an ionic solution is kept 
in  contact  with  ionic  resins.  The  drug  from  these  complexes  gets  exchanged  in 
 
gastrointestinal   tract   and   released   with   excess   of   Na+      and   Cl- present   in 
 
gastrointestinal tract. 
 
E. Methods using osmotic pressure: 
 
It  is  characterized  by drug surrounded  by semi  permeable membrane and 
 
release governed by osmotic pressure. 
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Advantages: 
 
Zero order release rates are obtainable. 
Preformulation is not required for different drugs. 
Release of drug is independent of the environment of the system. 
 
Disadvantages: 
 
System can be much more expensive than conventional counterparts. 
Quality control is more extensive than most conventional tablets. 
F. pH– Independent formulations: 
 
A buffered controlled release formulation is prepared by mixing a basic or 
acidic  drug   with  one  or  more  buffering  agents,  granulating  with  appropriate 
pharmaceutical excipients and coating with GI fluid permeable film forming polymer. 
When GI fluid permeates through the membrane the buffering agent adjusts the fluid 
inside to suitable constant pH thereby rendering a constant rate of drug release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.No.5: Drug delivery from environmentally pH sensitive release systems. 
G. Altered density formulations: 
Several approaches have been developed to prolong the residence time of drug 
delivery system in the gastrointestinal tract. 
High-density approach 
 
Low-density approach 
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Fabrication  of  oral  controlled  release  delivery  employs  various  methods:9 
 
Hydrophilic  matrix,  Plastic  matrix,  Barrier  resin  beads,  Fat  embedment, 
 
Repeat action, Ion exchange resin, Soft gelatin depot capsules and Drug complex. 
 
Hydrophilic Matrix System: 
 
Drug delivery technologists usually tend to consider all hydrophilic delivery 
systems as hydrogels. Hydrogels are hydrophilic macromolecular networks that after 
swelling maintain their shape due to permanent links.  The very high water content 
and  special  surface properties  of  swollen  form  give them  the ability to  simulate 
natural tissues10. 
 
They have been used in controlled drug delivery because of their good tissue 
compatibility   and   easy   manipulation   of   swelling   level   and   there   by   solute 
permeability11. 
 
The most widely used polymers for drug delivery control; particularly in oral 
 
applications are swellable polymers. 
 
Hydrogel based Drug Delivery Systems are classified as: 
 
Diffusion Controlled Release System 
 
a) Reservoir System:  It   consists   of   polymeric   membrane   surrounding   a   core 
containing the  drug. The rate-limiting step for drug release is diffusion through the 
outer membrane of the device. 
 
 
Fig. No.6: Hydrogel formation in Reservoir Systems. 
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b) Matrix System: 
 
The drug is dispersed through out the three dimensional structure of 
the hydrogel. Release occurs due to diffusion of the drug throughout the water filled 
pores. 
 
 
Fig. No.7: Hydro gel formation in Matrix System. 
 
 
Fig. No.8: Drug release from a matrix tablet 
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Types:  
 
• Swellable. 
 
• Non-swellable. 
 
Swellable Controlled Release Systems: 
 
During the release life of swellable matrix system, three fronts are generally 
expected. 
1.  The swelling front, the boundary between the still glassy polymer and its 
rubbery state. 
2.  The diffusion front, the boundary in the gel layer between the solid as yet 
undissolved, drug and the dissolved drug. 
3.  The  erosion  front,  the  boundary  between  the  matrix  and  the  dissolution 
medium. 
The measurement of front positions gives the possibility to determine three 
important parameters related to the behavior of the matrix i.e. the rate of water uptake, 
the  rate  of  drug  dissolution  and  the  rate  of  matrix  erosion  associated  with  the 
movements of the swelling front, diffusion front and erosion front respectively. 
These parameters are strictly linked to the drug release kinetics from matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig. No. 9: Parameter definitions for swellable soluble matrix 
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Ds – Solvent diffusion co-efficient in the drug/ polymer matrix. 
Dd – Drug diffusion co-efficient in the swollen polymers. 
 
Cs – Drug solubility at the drug core interface (R) 
 
C* - Drug volume fraction at the gel/solution interface 
 
C – Polymer volume fraction at R 
Cd – Polymer volume fraction at S. 
Ccp- Polymer volume fractioning in the glassy core 
 
Ccd - Drug volume fraction in the glassy core. 
 
Non-swell able controlled release systems: 
 
These systems are hollow containing an inner core of drug surrounded in a 
water insoluble polymer membrane. The polymer can be applied by coating or by wet 
granulation technique. The drug release mechanism across the membrane involves its 
partitioning into the membrane with subsequent release into the surrounding fluid by 
diffusion. 
The polymers commonly used in such devices are Hydroxy Propyl Cellulose, 
Ethyl Cellulose and Polyvinyl Acetate. A disadvantage of all such release system is a 
chance of sudden drug dumping which is not common with matrix devices. 
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AIM &OBJECTIVES 
• The basic goal of therapy is to achieve a steady state blood or tissue level that 
is  therapeutically effective  and  non-toxic  for  an  extended  period  of  time. 
Sustained release drug delivery systems, with an aim of improved patient 
compliance, better therapeutic efficacy, less side effects and reduced dosage 
regimen with less toxicity for treatment for many acute and chronic diseases. 
• Gliclazide is oral hypoglycaemic drug which lowers blood glucose level. It 
provokes  a   brisk  release  of  insulin  from  pancreas  and  shows  peculiar 
pharmacokinetic characteristics. It is extensively protein bound (87% to 94%) 
in circulation. It is first sulfonylurea for which it is possible to detail its action 
from the moment of oral administration through to it’s on long term glycemic 
control. Its plasma peak concentration occurs between 4 to 6 hours. Therefore, 
gastric and intestinal transient times have a significant effect on the rate and 
extent of oral absorption of the drug. 
• Matrix tablets are very useful in the field of healthcare for sustained release 
dosage regimen. 
• Keeping this in view, the present investigation has been aimed at designing 
suitable  sustained release matrix tablets using polymers as hydroxylpropyl 
methylcellulose and hydroxyl propyl cellulose. 
The major objectives of the investigation are as follows: 
 
 
1.  To perform preformulation studies like flowing properties & bulking density 
for powders of drug and polymers. 
. 
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2. To formulate matrix tablets of Gliclazide by wet granulation method by using 
different polymers like HPMC, HPC  
3.  To  evaluate  prepared  formulations  for  physical  parameters  like  weight 
variation, friability, and hardness etc. 
 
4.  To study swelling index behavior of selected formulation. 
 
 
 
5.  To study in-vitro drug release performance of different tablets formulations. 
 
 
6.  To study the effect of different polymers on drug release. 
 
 
7.  To ascertain the release mechanics and kinetics of drug release from 
compressed matrix tablets. 
8.  To perform stability studies as per ICH guidelines. 
 
 
BASIS FOR DRUG SELECTION AND DOSAGE SELECTION. 
 
• For  many drugs,  the  optimal  therapeutic  response  is  observed  only when 
adequate blood levels are achieved and maintained with minimum variations, 
(the matrix tablets will give more consistent blood levels). 
• Sulfonylurea with long half-life such as gliclazide has sustained stimulation on 
insulin  secretion  compared to repaglinide which has short half-life for only 
about 1 hr. 
• Gliclazide with biological half-life is 10 to 12hrs. It is oral hypoglycaemic drug 
which lowers blood glucose level and extensively protein bound in circulation. 
• It has been recommended for use on the basis of both its metabolic and non 
 
metabolic effects. 
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 DRUG & EXCIPIENTS PROFILE 
 
 GLICLAZIDE.12, 13, 14, 15 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C15 H21 N3 O3 S, Mol. Wt: 323.4 
 
Gliclazide, 1-(3-azabicyclo (3.3.0) oct-3-yl)-3-ptolylsulphonylurea is an oral 
hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus 
(NIDDM). It contains not less than 99.0 % and not more than the equivalent of 101.0% 
of 1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(4-methylphenyl)sulphonyl]urea, 
calculated with reference to the dried substance. 
 
Characteristics: 
 
A white or almost white powder. 
 
Solubility: 
 
Practically insoluble in water, freely soluble in methylene chloride, sparingly 
soluble in acetone, slightly soluble in alcohol. 
Pharmacological effects: 
Gliclazide is oral hypoglycaemic drug which lowers blood glucose level. It 
provokes a brisk release of insulin from pancreas and shows peculiar pharmacokinetic 
characteristics. 
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Pharmacokinetics: 
 
It  is  extensively  protein  bound  (87%  to  94%)  in  circulation.  It  is  first 
sulfonylurea  for which it is possible to detail its action from the moment of oral 
administration  through  to  it’s  on  long  term  glycemic  control.  Its plasma  peak 
concentration occurs between 4 to 6 hours. Therefore, gastric and intestinal transient 
times have a significant effect on the rate and extent of oral absorption of the drug. 
Therapeutic uses: 
This medication  is  used  in  conjunction with  diet  and  exercise regimens  to 
control high blood sugar in non-insulin dependent diabetic patients. Controlling high 
blood sugar helps prevent heart disease, strokes, kidney disease, circulation problems, 
and blindness. 
Preparation: 
 
Gliclazide tablets each containing 30 mg, 40 mg and 60 mg of Gliclazide are 
official in  USP and  BP. Tablets containing 30  mg and 40 mg of Gliclazide are 
available commercially in the market. 
 
Mechanism of action: 
Sulfonylureas provoke a brisk release of insulin from pancreas. They act on 
the so called sulfonylurea receptors (SUR1) on the pancreatic β cell membrane-cause 
depolarization by reducing conductance of ATP sensitive K+  channels. This enhances 
Ca 2+ influx degranulation. The rate of insulin secretion at any glucose concentration 
is increased. In type 2 DM the kinetics of insulin  release in response to glucose or 
meals is delayed and subdued. 
 
Dose: 
 
Adult dose: - 40 mg to 240 mg twice a day. 
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Side effects: 
 
Hypoglycaemia: - It is the commonest problem, may occasionally be severe and 
rarely fatal. It is  more commonly in elderly, liver and kidney disease patients and 
when potentiating drugs are added. 
Hypersensitivity:  -  Rashes,  photosensitivity,  purpurea,  transient  lukopenia,  rarely 
agranulocytosis. 
Nonspecific side  effects: - Nausea, vomiting, flatulence, diarrhea or constipation, 
headache, paresthesias and weight gain 
 
POLYMER PROFILE 16: 
 
 
 
HYDROXYPROPYL METHYLCELLULOSE 
 
 
 
Chemical name : Cellulose hydroxypropyl methyl ether 
 
Molecular weight : 10 000–1 500 000 
 
Chemical Structure: 
 
 
The substituent R represent either a-CH3 , or a –CH2 CH(CH3 )OH group, or a 
hydrogen atom. 
 
Description: 
 
Hypromellose is an odorless and tasteless, white or creamy-white 
 
fibrous or granular powder. 
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Melting point: Browns at 190–2000C; chars at 225–2300C. Glass transition 
temperature is 170–1800C. 
 
 
Viscosity (dynamic): A wide range of viscosity types are commercially available. 
Aqueous solutions are most commonly prepared, although hypromellose may also be 
dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol 
content is less than 50% w/w 
Incompatibility: - Hypromellose is incompatible with some oxidizing agents. Since it 
is nonionic,  hypromellose will not complex with metallic salts or ionicorganics to 
form insoluble precipitates. 
 
Stability and Storage: 
 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Hypromellose undergoes a reversible sol–gel 
transformation upon  heating and cooling, respectively. The gelation temperature is 
50–980C, depending upon the grade and concentration of material. For temperatures 
below the gelation temperature, viscosity of the solution decreases as temperature is 
increased.  Beyond  the  gelation  temperature,  viscosity increases  as  temperature  is 
increased. Hypromellose powder should  be stored in a well-closed container, in a 
cool, and dry place. 
Applications in pharmaceutical formulation or technology: 
 
Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Database (ophthalmic and nasal preparations; oral capsules, suspensions, 
syrups, and tablets; topical and vaginal preparations). Hypromellose has been used in 
pharmaceutical dosage forms produced  using hot-melt extrusion. Hypromellose is 
also used as a suspending and thickening agent in topical formulations. Hypromellose 
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is used as an emulsifier, suspending agent, and stabilizing agent in topical gels and 
ointments. 
HYDROXYPROPYL CELLULOSE 
 
Synonyms: Cellulose, hydroxypropyl ether; E463; hydroxypropylcellulosum; 
 
hyprolose; Klucel; Nisso HPC; oxypropylated cellulose. 
 
Chemical name: 
 
Cellulose, 2-hydroxypropyl ether 
 
Molecular Weight: 50000–1250000 
 
Structural Formula: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R is H or [CH2 CH (CH3 ) O] mH where m is a common integral number of cellulose 
derivatives. 
 
 
 
Description: - Hydroxypropyl cellulose is a white to slightly yellow-colored, odorless 
and tasteless powder 
Melting point: - Softens at 1300C; chars at 260–2750C 
 
Incompatibilities:   -   Hydroxypropyl   cellulose   in   solution   demonstrates   some 
incompatibility  with  substituted  phenol  derivatives,  such  as  methylparaben  and 
propylparaben.  The  presence  of  anionic  polymers  may  increase  the  viscosity  of 
hydroxypropyl cellulose solutions 
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Stability  and  storage  condition:  -  Hydroxypropyl  cellulose  powder  is  a  stable 
material,  although it is hygroscopic after drying. Hydroxypropyl cellulose powder 
should be stored in a well closed container in a cool and  dry place. 
Pharmaceutical Uses: 
 
Hydroxypropyl   cellulose   is   widely   used   in   oral   and   topical   pharmaceutical 
formulations. In oral products, hydroxypropyl cellulose is primarily used in tableting 
as  a  binder,  film-coating,  and  extended-release-matrix  former.  Concentrations  of 
hydroxypropyl  cellulose  of  2–6%  w/w  may  be  used  as  a  binder  in  either  wet- 
granulation or dry, direct compression tableting processes. Concentrations of 15–35% 
w/w of hydroxypropyl cellulose may be used to produce tablets with an extended drug 
release.   The   release   rate   of   a   drug   increases   with   decreasing   viscosity   of 
hydroxypropyl cellulose. It is also used in microencapsulation processes and as a 
thickening agent. Hydroxypropyl cellulose is also used in cosmetics and in food 
products as an emulsifier and stabilizer. 
Safety: Excessive consumption of hydroxypropyl cellulose may have  a laxative 
effect. 
DICALCIUM PHOSPHATE 
Non-Proprietary name: 
Calcium diphosphate. C-131<. 
 
Synonym: 
 
(DCP) dicalcium phosphate, calcium dihydrophosphate. 
 
Incompatibilities: 
 
With some drugs which form a complex (complexation reaction) and retain in 
kidneys as oxalate complexes. 
 
 
. 
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Chemical name: 
 
[CaHPO4 2H2 O] 
Molecular weight: 
 
172.10. 
 
Category: 
 
Tablet and capsule diluents and filler. 
 
Description: 
 
White to off-white powder. DCP is odorless and tasteless inert powder. 
 
Solubility: 
 
Insoluble in water and other organic fluids. 
 
Stability: 
 
Stable under humid conditions and no bacterial or mould growth occur, which 
is stable for prolonged storage. It is resistible to warm and damp conditions. 
Storage: 
 
To be stored in a well closed container, cool and dry place. 
 
Safety: 
 
Adverse reactions to DCP are very leastly attributed to intolerance, but may 
have  chance   of  accumulation  in  kidneys  as  cyst  and  stones  which  may  be 
complicative in rare cases. 
Particle size: 
 
(230 mesh #) – 98% passes. 
 
Minimum assay: 
 
98 – 102.5% 
 
Loss on drying: 
 
24.5 – 26.5% 
 
Loss on ignition: 
 
800ºC up to 80%. 
 
Substance insoluble in HCl: 
 
0.1%. 
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POLYVINYL PYRROLIDINE 
Synonym: 
Plasdone K-30, Luviskol K30, Plasdone, Povidone, PVP P, PVP-K 30; PVP; 
 
Polyvinylpyrrolidone;   Poly  [1-(2-oxo-1-pyrrolidinyl)  ethylene);   Povidone  K-30; 
Poly(n-vinlybutyrolactam);Poly(1-vinylpyrrolidinone); 
Chemical Name: Poly (1-vinyl-2-pyrrolidinone) 
 
Chemical Formula: (C6H9NO)n 
 
Chemical structure: 
 
 
 
Physical state and appearance: Solid. ( Powdered solid.) 
 
Odor: Odorless. 
 
Molecular Weight: (111.14) n g/mole 
 
Color: Creamy White. 
 
Boiling Point: 90°C (194°F) - 93 C 
 
Melting Point: 13.9°C (57°F) 
 
Specific Gravity: Density: 1.23 - 1.29(Water = 1) 
 
Incompatibility with various substances: Reactive with oxidizing agents 
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Solubility: 
 
 Soluble in cold water.  
 Soluble in water giving a colloidal solution. 
 Soluble  in  chloroform,  alcohol,  chlorinated  hydrocarbons,  amines, nitro 
 paraffin’s, lower weight fatty acids.  
 
Specification: 
 
1. Application: 
PVP K series  can be used as  film forming agent, viscosity-enhancement 
agent,  lubricator and adhesive. They are the key component of hair sprays, 
mousse, gels and lotions & solution. They are also convenience assistant in 
skin  care  product,  hair-drying   reagent,  shampoo,  eye  makeup,  lipstick, 
deodorant, sunscreen and dentifrice. 
           2. Pharmaceutical: 
Povidone K 30 and K 25 is a new and excellent pharmaceutical excipient. It is mainly  
used  as  binder  for  tablet,  dissolving  assistant  for  injection,  flow assistant for 
capsule,  dispersant for liquid medicine and pigment, stabilizer for enzyme and heat 
sensitive drug, co precipitant for poorly soluble drugs, lubricator  and  antitoxic  
assistant  of  eye  drug.   PVP  has  been  used  as excipients in more than one hundred 
drugs. 
Molecular Weight: 591.3 
       Structure: 
                                   CH
3
(CH
2
)
16
COO 
                                       Mg 
 
                                   CH
3
(CH
2
)
16
COO 
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Description:  
 
Fine, white, precipitated or milled, impalpable powder of low bulk density. 
Odor and taste are slight but characteristic. The powder readily adheres to the skin. 
Typical Properties: 
Solubility: 
Insoluble in  water,  alcohol  and  ether.  Slightly soluble in  hot  alcohol  and 
benzene. 
 
 
Stability and storage conditions: 
 
Stable, non-self-polymerizable. Store in a cool, dry place in a well closed 
container. 
Incompatibilities: 
 
Acidic substances; alkaline substances; iron salts.  Avoid mixing with strong 
oxidizing materials.  Use with caution with drugs, which are incompatible with alkali. 
Safety: 
It is described as an inert or nuisance dust.  Classified as non-hazardous by the 
Department of Transportation Regulations.  Dust clouds of magnesium stearate may 
be explosive. 
 
 
 
  
. 
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COLLOIDAL SILICON DIOXIDE 
 
 
Synonyms: Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica 
 
Chemical name: Silica 
 
Empirical formula: SiO2 
 
Molecular Weight: 60.08 
 
Structure: 
 
Description: It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous 
powder 
Melting point: 16000C 
 
Solubility:  Practically  insoluble  in  organic  solvents,  water,  and  acids,  except 
 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. 
 
Incompatibilites: Incompatible with diethylstilbestrol preparations. 
Stabilities  and  Storage  condition:  Colloidal  silicon  dioxide  is  hygroscopic  but 
adsorbs large quantities of water without liquefying. When used in aqueous systems at 
 
 
a pH 0–7.5, colloidal silicon dioxide is effective in increasing the viscosity of a 
system. Colloidal silicon dioxide powder should be stored in a well-closed container 
Application: Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, 
and food products. Colloidal silicon dioxide is also used to stabilize emulsions and as 
a thixotropic thickening and suspending agent in gels and semisolid preparations. In 
aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray 
nozzles. Colloidal silicon dioxide is also used  as a tablet disintegrant  and as  an 
adsorbent dispersing agent for liquids in powders.
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AN EXTENSIVE WORK WAS CARRIED ON MATRIX, SOME OF THEM 
ARE CITED BELOW. 
1. Jeyaprabha  P  et al  The purpose of this research work was to prepare a modified 
release tablet of gliclazide by using different grades of Hydroxypropyl cellulose. 
Infrared spectroscopy study showed that drug and  other excipients were compatible 
with each other. The granules were evaluated for angle of repose, bulk density and 
compressibility index. The tablets were evaluated to weight variation, thickness,  
hardness, friability, drug content, in-vitro drug release. The granules showed 
satisfactory flow properties. This study showed that release process involved erosion 
and diffusion. The Accelerated stability  study  was  also  performed  for  optimized  
formulation  for  three  months indicated that optimized formulation was stable.17 
2. Hindustan AA  et al The  formulation  was  to  design  matrix  type oral  tablets  of  
Gliclazide  with Azadirachta  indica fruit mucilage and Povidone. The polymers were 
studied for its functionality  as  a  matrix  forming  property  to  sustain  the  Gliclazide  
release  from formulated matrix tablets. Physicochemical properties of dried 
powdered mucilage of Azadirachta  indica  fruit  mucilage  and  Povidone  blend  
were  studied.  Various formulations  of  Gliclazide  Azadirachta  indica  fruit  
mucilage  and  Povidone  were prepared. The swelling behavior and release rate 
characteristics were studied. The in-vitro dissolution study proved that the dried 
Azadirachta indica fruit mucilage.18 
3. Sapkal NP  et al Gliclazide has been found to form inclusion complexes with β- 
cyclodextrin (β-CD) in solution and in solid state. The present study was undertaken to 
determine a suitable method for scaling up gliclazide-β-CD inclusion complex 
formation and to evaluate the effect of some parameters on the efficiency of 
complexation. 
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The solid inclusion complexes of gliclazide and β-cyclodextrin were prepared 
at a molar ratio of 1:1 and 1:2 by mixing, kneading, and coprecipitation methods both    
on small and large scales.Characterization was performed using infrared 
spectroscopy, X-ray diffractometry, and dissolution studies. In vitro release 
studies were carried out in phosphate buffer (pH 6.8).19 
 
4. Prameela RA  et al The  antidiabetic  drugs  are  poorly  soluble  in  water,  
which  affect  the bioavailability. In the present work, complex formation of all the 
three drugs with β- cyclodextrin (β-CD) and  Hydroxy propyl b- cyclodextrin (HPβ-
CD) and then the possibility of improving the solubility of NTG, RPG and GMP by 
complexation with β-CD,  HPβ-CD  were  investigated.  The  phase   solubility  
studies  indicated  the formation of Nateglinide-β-CD, Repaglinide-β-CD,  
Glimepiride-β-CD, Nateglinide- HPβ-CD, Repaglinide-HPβ-CD and Glimepiride-
HPβ-CD inclusion complexes at 1:1 M ratio in solutions with stability constant of 
345 M-1, 267 M-1,329 M-1, 433 M-1,319 M-1,  and  406  M-1  respectively.  The  
solubility  was  markedly  enhanced  by complexation with β-CD and HPβ-CD.20 
 
5. Moyano  JR  et al Solid complexes between gliclazide and fl-cyclodextrin (fl-CD) 
were prepared  by kneading, coprecipitation, neutralization, co-
rindingandspray-drying.Characterization of gliclazide-fl-CD inclusion complexes was 
performed using X-ray diffractometry  and  cross  polarizing/magic  angle  spinning  
~3C-nuclear  magnetic resonance spectroscopy. The complexes, obtained by 
neutralization and spray-drying methods, showed enhanced dissolution rates of 
gliclazide.21 
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6. Biswal S, Sahoo J et al Gliclazide SDs containing varying concentrations of PEG 
8000 were prepared using  the   fusion  –  solvent  technique,  and  their  phase  
solubility  behavior  and dissolution in 0.1N HCl were assessed at 370C. The physical 
state of, and gliclazide- PEG interactions in, SDs and physical mixtures prepared in 
ratios of 1:1, 1:2 and 1:5 (gliclazide: PEG 8000), respectively, were characterized by 
x-ray diffraction (XRD), Fourier-transform infrared (FTIR) spectroscopy and 
differential scanning Calorimetry (DSC).22 
 
7. Vijayalakshmi P et al The antidiabetic drug gliclazide has very poor aqueous 
solubility leading to variable bioavailabilities on oral administration thus posing 
problems in the design of controlled  release  tablets.  Therefore,  the  aim  of  the  
study  was  to  increase  the  solubility of the drug by making inclusion Complex 
with hydroxypropylbetacyclodextrin  in  the  ratio  1:2  and  to  incorporate  the  
solubility enhanced drug in matrix forming polymer like   
sodiumcarboxymethylcellulose for designing oral controlled release tablets.23 
 
8  Esra D, Levent O et al Gliclazide is a second generation sulfonylurea drug, 
characterized by poor solubility and, hence, by a low dissolution rate in water. This 
property causes inter- individual variations of its  bioavailability. The major 
drawback in the therapeutic application and efficacy of gliclazide as oral  dosage 
forms is its very low aqueous solubility because of its hydrophobic nature.24 
9. The  present  invention  relates  to  a  sugar-free  sustained-release  gliclazide 
 
formulation   omprising an intragranular part and an extragranular part, wherein the 
 
 
intragranular part comprises gliclazide or a salt thereof and the extragranular part 
comprises a cellulose-derived polymer, said intragranular part being binder-free.
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The sustained-release   formulation   of  the  inventionpreferably  consists  
essentially  of gliclazide or a salt there of a diluent - an extragranular cellulose-
derived polymer,  a lubricant and/or glidant.25 
 
10. Raida SA et al This  work  investigates  preparation  of  biodegradable  beads  
with  alginate polymer by  ionotropic gelation method to take the advantages of the 
swelling and mucoadhesive properties of  alginate beads for improving the oral 
delivery of the antidiabetic  agent  gliclazide.  It  demonstrates  that  the  ionic  
gelation  of  alginate molecules  offers  a  flexible  and  easily  controllable  process  
for  manipulating  the characteristics of the beads which are important in  controlling 
the release rate and consequently the absorption of gliclazide from the gastrointestinal 
tract. Variations in polymer  concentration,  stirring  speed,  internal  phase  volume  
and  the  type   of surfactant in the external phase were examined systemically for 
their effects on the particle size, incorporation efficiency and flow properties of the 
beads. The in vitro release experiments revealed that the swelling is the main 
parameter controlling the release rate of gliclazide from the beads.26 
 
11. Ambrogi  V  et al This paper deals with a new hydrotalcite-like compound used 
as a matrix to improve dissolution rate of the poorly water-soluble drug gliclazide and 
to administer at the same time micro-  and oligo-elements useful to improve insulin 
performance. Gliclazide is a second-generation  sulfonylurea compound used in the 
treatment of type II diabetes mellitus. As a consequence of the poor water solubility, its 
absorption is limited. Thus, a new hydrotalcite-like compound containing Zinc and 
Chromium, micronutrients directly involved in the physiology of insulin and in the 
carbohydrate, lipid and protein metabolism, was synthesized. The gliclazide-
hydrotalcite-like clay  
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nanohybrid was prepared via ion-exchange in its nitrate form and was characterized 
by inductively coupled plasma-optical emission spectrometry and thermogravimetric 
analysis. The intercalation product was submitted to solubility measurements and in 
vitro dissolution test.27 
 
12. Guntram S  et al Gliclazide modified release (MR) is a new formulation of 
the drug gliclazide and is given  once daily. The specifically designed hydrophilic 
matrix of gliclazide MR leads to a progressive drug release that parallels the 24-hour 
glycemic profile in type 2 diabetic patients. Development  studies showed a 
sustained efficacy over 2 years  coupled  with  a very good  acceptability.  Gliclazide  
MR  acts  selectively on adenosine triphosphate–dependent potassium (KATP ) channels 
of the pancreatic β cell. No interaction with cardiovascular KATP  channels has been 
shown, indicating that the drug can be safely used in patients with ischemic heart 
disease.28 
13. Saify  ZS et al  The goal of rational drug therapy is to produce a desired 
pharmacological response in an acceptable and predictable manner while minimizing 
the occurrence of undesired events. The Pharmacokinetics of different generics of 
tablet gliclazide 80 mg was investigated on healthy (10 x 2), Pakistani subjects. For 
this exploration an open-label, randomized, two period crossover (Balanced in 
Complete Block Design) study, was conducted The outcome of the said study 
suggests that all generics were found  analogous  regarding  pharmacokinetic  
behavior  in-spite  of  having  different excipients,  concentration  of  excipients,  
sources  of  raw  material,  manufacturing process, machinery, resources and also inter 
individual variation of the study. Results of  the  study  also  undoubtedly  advocate  
that  generics  manufactured  in  different manufacturing units of Pakistan are  near 
to the standard formulation and produce comparable results. No significant  
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       differences in  pharmacokinetics parameters were observed, however, minor 
differences might narrate with inter individual variation in human volunteers and in 
different generic as well as different pharmaceutical unit.29 
 
14. Hong SS et al A soft gelatin capsule containing PEG 400, PEG 4000, Tween 20 
and glycerin was prepared  as a formulation that may accelerate dissolution of 
gliclazide. The in vitro  dissolution  of  gliclazide  at  pH  7.2  was  identical  for  the  
soft  capsule  and conventional  tablets,  Diamicron  and  Diberin.  However,  at  pH  
1.2  and  4.0,  the dissolution from the soft capsule was more rapid compared to  
the tablets. When bioavailability parameters were compared following oral 
administration of the  soft capsule  and  Diamicron  to  16  healthy  Korean  male  
subjects,  the  parameters representing  the  amount  of  absorption  (i.e.  the  area  
under  the  serum  gliclazide concentration vs. time curve up to 24 h, AUC, and the 
peak serum concentration, C ) were not  statistically different  for both  formulations.  
However,  the time 24  max required to reach the peak (T) was significantly shorter 
for the soft capsule than for the Diamicron. Our results, therefore, max indicate that 
a rapid  elevation  of serum gliclazide  concentration  following  oral  administration  
of  a  formulation  can   be achieved by accelerating the in vitro dissolution of 
gliclazide from the formulation into  the  acidic  buffers.30 
 
   15 Varshosaz J et al Gliclazide (GL) is a second-generation sulphonylurea, widely 
used for the treatment of non-insulin dependent diabetes mellitus. The low water-
solubility of GL leads to a low dissolution rate and variable bioavailability. The aim 
of this study was to enhance the dissolution rate of GL by the preparation of micron-
sized particles using a solvent change method.  
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stabilizing agents. GL (0.5 or 1 g) was dissolved in acetone and the stabilizing agent 
in water (as non-solvent). The non-solvent was poured rapidly into the drug solution 
under stirring at 26,000 rpm by an ultra-homogenizer, and the resultant was freeze- 
dried. The crystalline shape  of GL changed from rod-shape to diamond- or cube- 
shape. The FTIR and DSC results showed no interaction between the drug and the 
stabilizers. Presence of sharp peaks in the XRD diffract grams of micro crystals with 
10 times  smaller  height  than  untreated  crystals  indicates  that  a  crystalline  habit 
modification has occurred in the microcrystal without any polymorphic changes..31 
 
16. Ozkan Y et al Inclusion complexes of gliclazide with β-cyclodextrin were 
prepared using   different   two   methods:   neutralization   and   recyristalization.   
Host–guest interactions  were  studied  in  the  solid  state  by  X-ray  diffractometry  
and  infrared spectroscopy.  The  stability  constant  between  gliclazide  and  β-
cyclodextrin  was calculated from the phase solubility diagram.  It was found that 
the neutralization technique and a solid complex of gliclazide with β-cyclodextrin  in 
a molar ratio of 1.5:1 could be used to prepare the amorphous state of drug inclusion 
complexes. The dissolution rate of gliclazide from the inclusion complex made by 
neutralization was much  faster  than  the  pure   drug,  physical  mixture  of  drug  
and  cyclodextrin, recyristalization system and also comparable to the data reported in 
literature. 32 
 
17. Revathi  R et al A simple, sensitive and accurate UV spectrophotometric method 
has been developed for the determination of gliclazide in bulk and pharmaceutical 
tablet dosage formulations. This method obeys Beer’s law in the concentration range 
of 5 -30 ȝg/mL with correlation coefficient of 0.9956 and exhibiting maximum 
absorption 
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at 224 nm with apparent molar absorptivity of 0.1236×103  Lmol-1cm-1. The method is 
accurate and precise and is extended to pharmaceutical tablet dosage forms and there 
was no interference from any common pharmaceutical additives and excipients.33 
 
18. Kathiresan K et alThe present s tud y was  a imed  to  fo rmul a t ion  and  
deve lopm ent  of indomethacin sustained release tablets by wet granulation method. 
The main objective of this work is decrease the dosage frequency, to decrease dose 
dumping, increase the patient  compliance  and  to   enhance  the  desired  activity  by  
adopting  the  wet granulation  technique.  In  this  study,   excipients  are  selected  
in  four  different concentrations (F-1, F-2, F-3, and F-4) and formulated  by  wet 
granulation method. Then all four formulations are evaluated. By observing the 
dissolution profile of trials, trial-4 (formulation-4) was better formulation of all the 
trails. In trial-4 indomethacin was formulated as sustained release tablets by using 
ethyl cellulose and HPMC k-100. And that having good dissolution profile for a 
controlled period of time which shown 83.4% at end of 12th hour.34 
19. Dr. Shivhare UD et al Once daily sustained release tablets of aceclofenac were 
formulated by  wet  granulation  using  carboxypolymethylene  polymer.  The  drug  
excipient mixtures were subjected to preformulation studies while the tablets were 
subjected to physicochemical studies, in vitro drug release, stability studies and 
validation studies. Formulation F2 & F9 containing Carbopol 971P and Carbopol 
974P were found to release the drug in sustained manner up to 24 hour and were 
stable under accelerated conditions of temperature for 6 months since there were 
no significant changes in drug content and physical parameters.35 
 
20. Raghvendra rao NG et al Sustained   release   matrix   tablets   of   water   
soluble   tramadol hydrochloride  using  different  polymers  viz.  hydroxy  propyl   
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methyl  cellulose (HPMC) and  natural gums like karaya gum (KG) and 
carrageenan (CG). Varying ratios of drug and polymer like 1:1 and 1:2 were 
selected for the study. After evaluation of physical properties of tablet, the in vitro 
release study was performed in 0.1N HCl pH 1.2 for 2 hrs and in phosphate 
buffer pH 6.8 up to 12 hrs. The effect of polymer concentration and polymer 
blend concentration were studied.36 
        21. Patel  R, et al  Sustained  release  matrix  tablet  of  theophylline  were  
formulated  by using different grades of hydroxypropyl methyl cellulose were 
evaluated for gel forming properties. The effects of polymers concentration on drug 
release profile were investigated. A 32 full factorial design was applied to 
systemically optimize the drug release profile. The amounts of HPMC K-4M (X1) 
and HPMC K-100M (X2) were selected as independent variables. Cumulative % 
release of drug for 1st hour and 8th hour were selected as dependent variables. The 
results of  the full factorial design indicated that a low amount of HPMC K-100M and 
a high amount of HPMC K-4M favors sustained release of theophylline from matrix 
tablet.37 
22. Hiremath  P.S.,  et al   Controlled release matrix tablet of Rifampicin 
and isoniazid combination,  to  study  the  design  parameters  and  to  evaluate  in  
vitro  release characteristics. In the present study, a series of formulations were 
developed with different release rates and  duration using hydrophilic polymers 
hydroxypropyl methylcellulose (HPMC) and  hydroxypropyl  cellulose (HPC). 
The duration of rifampicin and isoniazid release could be  tailored by varying 
the polymer type, polymer   ratio   and   processing   techniques.   Further,   
Eudragit   L100-55   was incorporated in the matrix tablets to compensate for the 
pH-dependent release of rifampicin.38 
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23. Savaser A et al The effects of formulation variables on the release profile of 
diclofenac sodium (DS)  from hydroxyl propyl methyl cellulose (HPMC) and 
chitosan matrix tablets  were  studied.  DS  tablets  were  prepared  by  wet  
granulation  and  direct compression methods and different ratios of HPMC and 
chitosan were used. Physical properties of  the  prepared tablets and targeted 
commercial sustained release (SR) tablet and the drug release were studied in tablets 
that were placed in 0.1M HCl for 1 hr and phosphate buffer solution was added to 
reach pH value of 7.5. In vitro studies showed that 20% HPMC contained SR 
formulation  with direct (dry) compression method is the optimum formulation due 
to its better targeting  profile  in terms of release.39 
 
24. Toshiaki  N et al The  sustained-release  tablet  of  sodium  diclofenac  (SR-
tablet)  was prepared  simply by mixing sodium diclofenac with hydrogenated 
soya lecithin without any other  additive. The dissolution of sodium diclofenac 
from the SR- tablet occurred in an apparent zero-order kinetics process with 90% 
release at 24 hr.  The  human  subjects  to  whom  the  SR-tablet  was  
administered  excreted diclofenac in urine gradually up to 24 hr. However,  
they excreted diclofenac rapidly and no more excretion of diclofenac was 
observed 9 hr after administration of the conventional tablets.40 
 
25. Lütfi G,  e t  a lMatrix tablets of ketorolac tromethamine (KT) were prepared 
by direct compression  technique  and  Carbopol  934,  940  and  1342  have  been  
used  as polymers in different concentrations (5-15 %).The in vitro release 
kinetics of ten different formulations of KT matrix tablet were studied. According 
to our results, different types and concentrations of carbopol to tablet formulations 
may effect incontrolled drug release.41 
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26. Sasidhara  RLC  et al Verapamil HCl was formulated as an oral CR matrix 
tablets by using poly (ethylene oxides) {Polyox WSR 303 and Polyox WSR 
301}. In this study, the matrix tablets were prepared by direct compression 
method. The drug release from the formulations followed first order kinetics and 
were linear with Higuchi plots. The  in  vitro  drug  release  studies  for  different  
formulations  were  also compared  with  drug  release  studies  of  commercially  
available  products.  The results indicated that the formulations containing drug 
and polymer ratio 1:0.5 for Polyox WSR 303 and 1:1 for Polyox  WSR 301 for 
Verapamil HCl were linear with drug release rates of marketed products. The  
formulations containing drug and polymer ratio 1:1, 1:1.5 for Polyox WSR 303 
and 1:1.5 for Polyox WSR 301 showed  greater  inhibition  on  release  rate  of  
Verapamil  HCl  from  the  tablet matrix.42 
27. Baveja SK et al  Sustained  release  tablet  dosage  form  of  centperazine,  a  
pale  yellow viscous oily  liquid, freely soluble in  water and  all common polar 
and  non-polar solvents, was prepared using hydrophilic polymers as matrix materials. 
A formulation containing centperazine, Aerosil 200, sodium carboxy methyl cellulose 
(NaCMC) and hydroxyl propyl methyl cellulose (HPMC) in the ratio of 1: 0.7: 4: 4 
was found to be the best in the study when tested in vitro and in vivo (man) giving 
linear release for about 12 hr. The release of drug from this formulation was found to 
be independent of hardness of tablet and pH of the dissolution medium.43 
 
28. Pandey  VP et al Diltiazem hydrochloride was formulated as sustained release 
tablet using hydroxy propyl methyl cellulose (methocel), ethyl cellulose and eudragit 
as sustaining materials in various proportions and differed in hardness. Study 
indicated that higherhardness slowed the release pattern in dissolution study. 45 
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29. Patra CHN et al Controlled release formulation of propranolol hydrochloride 
using guar gum as a carrier  and  also to study the influence of some cellulose 
ethers like sodium carboxymethyl cellulose, hydroxy propyl methyl cellulose, 
hydroxy propyl cellulose and ethyl cellulose on the in-vitro release of propranolol 
hydrochloride from guar gum matrix tablets. In-vitro release studies indicated that 
30% of guar gum and cellulose ethers   were   found   to   be   effective   in   
retarding   the   release   of   propranolol hydrochloride. 46 
 
30. Harrian, Ghaffari e t  a l  Different retardant polymers including carbopol 934P, 
hydroxy propyl methyl cellulose  (HPMC K4 M) and eudragit NE 30 D, RL 30 D 
and RS 30 D as rate controlling materials  were  evaluated. The influence of 
variable including polymer type, drug: polymer ratio, tablet filler type and tablet 
hardness on isosorbide dinitrate release profile was discussed. From the retardant 
polymers investigated. Eudragit NE 300 D exhibited proper release characteristics.47 
 
31. Farid   DJ et al The effect of various polymers on the release of nifedipine 
from their matrix was evaluated. In-vitro release profile of nifedipine from eudragit 
RS matrix showed that increasing the concentration of eudragit RS resulted in 
reduction of the release rate of nifedipine.48 
 
32. Hajare AA et al Diltiazem hydrochloride matrix tablets were fabricated by 
using of polymers like   guar   gum   (GG),   sodium   carboxymethyl   cellulose   and   
hydroxy   propyl methylcellulose  (HPMC)  polymers  by  wet  granulation  method  
and  evaluated  for various physical characteristics, drug  polymer interaction and in-
vitro drug release and for stability. The results were found that HPMC  and GG 
were show excellent sustained release and found to follow zero order.49 
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33. Behl Ak et al Formulation of ofloxacin tablets by various polymers hydroxy 
propyl methyl cellulose  K4 M, hydroxy  propyl  methyl  cellulose  E5   and  effect  of  
lubricant  was studied. Study showed that  hydroxypropyl methyl cellulose is 
appropriate polymer and preparation of matrix by wet granulation was found to be 
more effective.50 
34. Thapa P et al Study  was   carry  out   influence  of  different  diluents,carbopol  
934   P concentrations and granulation technique in the release of poorly water 
soluble drug  (ibuprofen) from carbopol 934 P matrix tablets. A significant effect of 
granulation technique, polymer concentration in the drug release rate from carbopol 
934P matrix based tablets was observed.  Diluents had appreciable effect on drug 
release rate only at low polymer concentration.51 
 
35.Mutalik S et al Once daily sustained release tablets of Aceclofenac were 
prepared by direct compression  using hydroxyl propyl methyl cellulose-K4 M 
(HPMC). By comparing the dissolution profiles with the marketed product, the tablet 
containing HPMC (45%) and  microcrystalline  cellulose  (30%)   along   with  talk  
and  magnesium  Stearate (1%w/w each) was considered as a better formulation.52 
 
 
36. Tabandesh H et al Matrix tablets of aspirin were prepared using ethyl cellulose, 
eudragit RS100 (RS) and  eudragit S100 (S) by direct compression. The release 
behavior were then studied in two counterpart  series of tablets with varied hardness 
and compared by non-linear  regression  analysis.  The studied  indicated  that  ethyl  
cellulose with  an amount as little as 10% was used  to make sustained release 
aspirin tablets in which the release profile was not sensitive to moderate changes in 
hardness.53 
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37. Udupa N et al Sustained released tablets of salbutamol sulphate were prepared by 
granulation method using PVP K-30, EC, sodium CMC, eudragit L-100, eudragit 
RL-100, guar gum etc as rate controlling agent. The studied indicated that 
combination of eudragit and beeswax produce more prominent sustained action of 
salbutamol.54 
 
38. Conti S et al Matrix tablets containing a soluble drug were prepared by using 
polymer hydroxy  propyl  methyl  cellulose  (HPMC)  and  sodium  carboxy  methyl  
cellulose (NaCMC)  alone  and  in  combination.  To  evaluated  the  effect  of  the  
dissolution medium at pH 1, 4.5 and 6.8. In vitro release studies showed that the 
mixture of the two cellulose derivatives enables a better control of the drug release 
profiles at pH 4.5 and at 6.8 both in term of rate and mechanism.55 
 
 
39. Kiortsis  S et al Four drugs differing in solubility (diclofenac sodium, ibuprofen, 
naproxen and indomethacin), two cellulosic polymers (HPC and HPMC) and 
hydrophobic Envelope were used in two levels of  mass fraction and weight ratio of 
drug: carrier and of cellulosic–hydrophobic component. It was found that for the 
release mechanism most significant was the effect of drug solubility followed by  
cellulosic polymer type, mixing procedure and drug mass fraction. Depending on the 
drug solubility and type of polymer present, wet granulation can increase or decrease 
the release rate.56 
 
40. Katikaneni  PR et al Pseudoephedrine  hydrochloride  was  used  to  prepare  
direct  compression sustained  release tablets with different viscosity grades of ethyl 
cellulose (EC). An increase in viscosity grade resulted in a marginal to moderate 
increase in the release  
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rate.   However,   lower   viscosity   grades   produced   harder   tablets.   The   highly 
compressible 10 cp grade was used to study the effect of drug loading, particle size, 
compression force, and magnesium stearate concentration on release properties. The 
square of drug release decreased with a decrease in the drug concentration in the 
matrix.57 
41. Sung KC et al Effect   of   two   formulation   variables,   hydroxyl   propyl   
methylcellulose (HPMC)/lactose  ratio  and  HPMC  viscosity  grade,  on  the  release  
of  adinazolam mesylate drug and HPMC from HPMC-based matrix tablets was 
studied. Both drug and HPMC release were  found to be a function of the 
formulation variables, with higher drug and HPMC release rates for formulations with 
lower HPMC/lactose ratios and lower HPMC viscosity grades. It was concluded that 
diffusion of drug through the hydrated gel layer was the predominant drug release 
mechanism for  most of the formulations studied .58 
 
                  42.  Pather SI et al Sustained  release  theophylline t blets  by  direct  compression  by  use  of 
 
ethylcellulose  were  investigated.  Matrices  of  this  polymer  display  slow  surface 
 
 
erosion  which  can  be  enhanced  by  the  incorporation  of  a  swelling  agent.  The 
theophylline to ethyl cellulose ratio and the tablet hardness were found to influence 
the rate of drug release.59 
 
 
43. Gil EC  et al The sustained-release matrix tablets of propranolol hydrochloride 
(PPL) were prepared by polymer like native dextran, hydroxyl propyl 
methylcellulose (HPMC), cetyl alcohol alone and binary mixtures of them and release 
in-vitro was investigated. The sustained-release matrix tablets were obtained with 
matrix excipients: PPL ratio of 60:40 (w/w), with a dextran: HPMC ratio of 4:1  
(w/w) and with a cetyl alcohol amount of 15% (w/w).
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A comparative kinetic study of the present matrix tablets and commercial 
sumial retard capsules was established. The value for the similarity factor suggested 
that the dissolution profile of the present two sustained-release oral dosage 
forms were similar.60 
 
44. Huang  YB,   et al  Once-daily  extended  release  propranolol  matrix  
tablets  were  formulated containing HPMC, microcrystalline cellulose (MCC) and 
lactose. The in-vitro studies were  carried  out  by  surface  methodology  and  
polynomial  equation.  The  results showed that the mechanism of drug release from 
HMPC matrix tablets followed non-Fickian diffusion.61 
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MATERIALS & METHODS 
 
The following materials that were either AR/LR grade or the best possible pharma 
grade available were used as supplied by the manufacturer. 
 
TABLE No- 1.MATERIALS USED 
 
 
MATERIALS 
 
GRADE 
 
COMPANY 
 
Gliclazide 
 
Pharma 
Zhejiang Jiuzhou Pharmaceuticals 
Co., Ltd. China. 
 
HPMC K4M 
 
Pharma 
 
Colorcon asia Pvt.Ltd. 
 
HPC 75-100 
 
A.R. 
 
Twilight Litaka Pvt Ltd. Pune. 
 
Di-calcium Phosphate 
 
-- 
 
Enar Chem. 
 
Pvp K30 
 
L.R. 
 
ISP tech inc. 
 
Magnesium Stearate 
 
A.R. 
 
Sunshine Organics. 
 
Aerosil 
 
A.R. 
 
Cabot sanmar. 
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Table No – 2. INSTRUMENTS AND EQUIPMENTS USED 
 
 
S.No 
 
Instruments/Equipments 
 
Company 
 
1. 
 
Electronic balance 
 
Shimadzu 
 
2. 
 
Hardness tester 
 
Incorp. 
 
3. 
 
Friability test apparatus 
 
Roche Friabilator 
 
4. 
 
Hydraulic press 
 
Rimek Mini Press – 1 
 
5. 
 
Vernier 
 
Ayesh. 
 
6. 
 
Tablet dissolution tester (USPXX III) 
 
Electro Lab 
 
7. 
 
Density Tap tester 
 
Electro Lab 
 
8. 
 
UV Spectrophotometer 
 
Shimadzu 
 
9. 
 
FTIR Spectrophotometer 
 
Shimadzu 
 
10. 
 
pH meter 
 
Contech. 
 
11. 
 
Humidity chamber 
 
Thermo Lab. 
 
12. 
 
Coating machine 
 
Biochem. 
 
13. 
 
HPLC 
 
Shimadzu 
 
 
14. 
 
 
Hot air oven 
 
Tempo Instruments and 
Equipments (I) Pvt. Ltd. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 
Chapter-V Methodology 
 
 
 
 
METHODS 
 
I. Preparation of calibration curve. 
 
1) Preparation of standard graph of Gliclazide using Phosphate buffer pH 7.4 
 
II. Compatibility studies. 
 
III. Evaluation of Pre-compression parameters. 
IV. Formulation of tablets of Gliclazide. 
1) Preparation of sustained release matrix tablets of Gliclazide with HPMC 
 
2)  Preparation of sustained release matrix tablets of Gliclazide with HPC. 
 
3) Preparation of sustained release matrix tablets of Gliclazide with HPMC & 
HPC.  
         V. Composition of Matrix tablets of Gliclazide 
VI. Evaluation of the prepared formulation for Physico-Chemical characteristics. 
VII. In-vitro drug release studies using phosphate buffer pH 7.4. 
VIII. Determination of assay and relative substances 
 
IX. Data analysis (curve fitting analysis). 
X. Stability studies. 
I. PREPARATION OF CALIBRATION CURVE 14. 
 
1). Preparation of standard graph of Gliclazide using phosphate buffer pH 7.4. 
 
Beer’s law is obeyed in the concentration range of 5 – 25 mcg/ml. 
 
Method:- 
 
50  mg  of  Gliclazide  was  accurately  weighed  into  100ml  volumetric  flask  and 
dissolved in  phosphate buffer pH 7.4. The volume was made up to 100ml to get a 
concentration of (0.5 mg/ml.) stock solution- I. From this, 1 ml was withdrawn and 
diluted to 10 ml to get a concentration of (25 µg/ml) stock solution -II. 
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Scanning of Drug:- 
 
From stock solution-II (SS-II), 4 ml was withdrawn and the volume was made 
up to 10 ml with phosphate buffer pH 7.4 to get a concentration of 10 µg/ml. UV scan 
range was taken between the wavelengths 200-400 nm. It gave a peak at 226 nm and 
290 nm and the same was selected as Ȝmax for Gliclazide. 
 
 
 
 
Calibration curve in phosphate buffer pH 7.4:- 
 
From  the  standard  stock  solution-II  (SS-II)  2,  4,  6,  8  and  10  ml  were 
withdrawn and volume ware made up to 10 ml with phosphate buffer pH 7.4 to give a 
concentration of 5, 10, 15, 20  and 25 µg/ml. Absorbance of these solutions ware 
measured against a blank of phosphate buffer  pH 7.4 at 266 nm and 290 nm for 
Gliclazide and the absorbance values ware summarized in Table 5. Calibration curve 
was plotted, drug concentrations versus absorbance was given in the Fig. 14. 
 
 
 
II. DRUG-EXCEPIENTS COMPATIBILITY STUDIES BY FTIR. 
 
 
Excipients are integral components of almost all pharmaceutical dosage forms. 
The successful formulation of a stable and effective solid dosage form depends on the 
careful  selection  of  the  excipients,  which  are  added  to  facilitate  administration, 
promote the consistent release and  bioavailability of the drug and protect it from 
degradation. 
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Fig no-10 Schematic representation of compatibility studies 
 
Infra Red spectroscopy is one of the most powerful analytical techniques to 
identify functional groups of a drug. 
Method: - 
 
The pure drug and its formulation were subjected to IR studies. In the present 
study, the potassium bromide disc (pellet) method was employed. 
 
 
 
III. EVALUATION OF PRE-COMPRESSION PARAMETER.17 
 
1) Angle of Repose (θ):- 
 
This is the maximum angle possible between the surface of a pile of powder or 
granules and the horizontal plane. 
The powders were allowed to flow through the funnel fixed to a stand at definite 
height (h). The  angle of repose was then calculated by measuring the height and 
radius of the heap of granules formed. 
tan θ  = h/r   θ = tan-1 (h/r) 
Where, θ = angle of repose 
h = height of the heap 
r = radius of the heap 
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Table no-3The relationship between Angle of repose and powder flow 
 
Angle of repose Powder flow 
< 25 Excellent 
25-30 Good 
30-40 Passable 
> 40 Very poor 
 
 
 
2) Compressibility Index:- 
 
The flow ability of powder can be evaluated by comparing the bulk density (Do) and 
tapped density (D f) of powder and the rate at which it packed down. Compressibility 
index is calculated by – 
Compressibility index (%) =  D f – D o x 100 
 
D f 
Where Do = Bulk density 
D f = Tapped density 
Table no-4The relationship between  Percent compressibility and Type of  flow 
 
 
Percent compressibility Type of flow 
5-15 Excellent 
12-16 Good 
18-21 Fare-passable 
23-25 Poor 
33-38 Very poor 
>40 Extremely poor 
 
 
3) Hausner’s ratio: - 
 
It is the ratio of tapped density to bulk density. 
 
Hausner’s ratio = D f/ Do 
 
                             Where Do = Bulk density 
                                         D f = Tapped density 
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4) Content Uniformity: - 
 
The granules were crushed and power containing 100 mg of Gliclazide was 
dissolved in 100 ml of methanol. The solution was passed through a whatmann (No. 
1) filter and analyzed spectrophotometrically at 226 nm and 290 nm after sufficient 
dilution with distilled water. 
 
 
 
IV. FORMULATION OF MATRIX TABLETS OF GLICLAZIDE.80 
 
1).  Preparation  of  sustained  release  matrix  tablets  of  Gliclazide  with 
 
HPMC/HPC or both retarding material. 
 
• Weigh and shift the Gliclazide, Di-Calcium phosphate through mesh # 40. 
 
• Weigh the PVP K-30 and dissolve in water by means of mechanical stirrer. 
 
• Dry mix the step one material in planetary mixer for 10 min. 
 
• Add the above binder solution into it with in 2-3 min run the planetary mixer 
at slow speed for 8-10 min and at high speed for 2-3 min. Add extra water if 
require. 
• Semidry granules at 60 0C for 30-40 min, passed through mesh #20, again dry 
 
it till LOD (2-3%). 
 
• Weigh the HPC 75-100, HPMC K-4M, magnesium stearate and aerosol passed 
through mesh #40. 
• Lubricate it for 5 min with step 4 blend and check the blend parameter. 
 
• Compressed  tablet  using  punch  size  10  mm  with  16  station  compressed 
machine. 
• And finally check in process parameter. 
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V. Table No.5. Composition of Matrix tablets of Gliclazide. 
 
 
 
VI. EVALUATION OF THE PREPARED FORMULATION FOR PHYSICO- 
CHEMICAL CHARACTERISTIC.17 
All prepared matrix tablets were evaluated for the following parameters. 
 
1) Shape of Tablets:- 
 
Tablets were examined under the magnifying lens for the shape of the tablet. 
 
2) Tablet Dimensions: - 
Thickness and diameter were measured using a calibrated vernier caliper. 3 
tablets  of  each  formulation  were  picked  randomly  and  thickness  was  measured 
individually. 
 
 
Ingredients 
(mg/tablet) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Gliclazide 60 60 60 60 60 60 60 60 60 
HPC 75-100  60 
 
70 
 
80 
 
--- 
 
--- 
 
--- 
 
30 
 
30 
 
30 
 
HPMC K4M 
 
--- 
 
--- 
 
--- 
 
60 
 
70 
 
80 
 
30 
 
40 
 
50 
Di-calcium 
Phosphate 
 
215 
 
205 
 
195 
 
215 
 
205 
 
195 
 
215 
 
205 
 
195 
 
PvpK30 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
Magnesium 
Stearate 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
Aerosil 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Water 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
q.s. 
 
Total weight 
 
350 
 
350 
 
350 
 
350 
 
350 
 
350 
 
350 
 
350 
 
350 
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3) Weight variation: - 
 
The causes for weight variation can be divided into granulation and 
mechanical problems. If the granule size is large, the dies will not be uniformly filled. 
Similarly mechanical problems can be traced of lower punches of non-uniform length. 
Method: - Uncoated tablets complies this test.  The average weight is determined by 
weighing 20 tablets. Not more than two tablets deviate from the average weight by a 
percentage greater than that  given and no tablet deviates by more than double that 
percentage. Weight variation tolerances for uncoated tablets: 
 
Table no-6  The  allowed weight variation of tablets  
Average Weight of Tablets (mg) Maximum Difference Allowed (%) 
130 or less 10 
130-324 7.5 
More than 324 5 
 
 
4) Hardness: - 
 
Hardness  was  measured  using  Incorp  Hardness  tester  that  measures  the 
pressure  required to break diametrically placed matrix tablets by applying pressure 
with coiled spring. 
 
5) Friability: - 
The friability of tablets was determined by using Roche friabilator. It is 
expressed in percentage (%). 6 tablets were initially weighed (Winitial) and transferred 
into friabilator. The friabilator was operated at 25 rpm for 4 minutes or run up to 100 
revolutions.  The tablets  were  weighed  again  (Wfinal). The % friability was  then 
calculated by- 
%F = 100 (1-W0/W) 
 
% Friability of tablets less than 1% was considered acceptable.
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6) Drug Content: - 
 
The drug content, 1 tablet was crushed and powder containing 100 
mg of Gliclazide was dissolved in 100 ml of distilled water. The solution was passed 
through a whatmann (No. 1) filter and analyzed spectrophotometrically at 226 nm and 
290 nm after sufficient with distilled water. 
 
 
 
7) Swelling Study: 
 
 
 
The swelling behavior of a dosage form was measured by studying its weight 
gain or water  uptake. The dimensional changes could be measured in terms of the 
increase in tablet diameter and/or thickness over time. Water uptake was measured in 
terms of percent weight gain, as given by the equation. 
WU = (Wt  – W0) X 100 
 
W0 
 
Wt  = Weight of dosage form at time t. 
W0  = Initial weight of dosage form 
 
 
VII. IN-VITRO DRUG RELEASE STUDIES USING PHOSPHATE BUFFER 
 
pH 7.4.14 
Theoretically, an in-vitro test for drug availability should measure in reality 
the physical  phenomenon  controlling availability in-vivo.  This  is  not  feasible for 
orally administered dosage forms because G.I fluids are not constant in composition 
and the dosage form moves at some unknown rate through the number of fluids. It is 
not possible to simulate a single test system which would incorporate reflection of all 
 
 
such variables as interaction between drugs and constituents, changes in volume, 
retention time, transit time and various other levels of agitation.
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However in-vitro test can be carried out which will indicate the effects of 
these variables on the mechanism and kinetics of drug release from a dosage form. 
This will give an idea of how the dosage form will behave when subjected to in-vivo 
studies. 
Determination of Dissolution Pattern: - 
 
Freshly prepared test media of 900 ml was placed in dissolution vessels of 
dissolution test  apparatus USP XXIV model. Six samples of the matrix tablet of 
Gliclazide (after weighing) was placed in 6 different jar containing dissolution media 
and temperature was maintained at 37.5 ±10C and paddle was rotated at the speed of 
100 rpm. At the specified time interval withdraw 5 ml sample solution from each 
vessel and filter. Further dilute the sample upto 25ml with dissolution medium. 
Then measure the absorbance of standard and sample solution in 1 cm cell on 
a suitable UV spectrophotometer at 226 nm and 290 nm, using dissolution as blank. 
Correct the absorbance obtained at 226 nm by subtracting the absorbance obtained at 
290 nm. Record the absorbance and calculate the percentage of Gliclazide dissolved 
in dissolution media by using following formula. 
 
Drug release = Conc. of Gliclazide x Dilution Factor x Dissolution medium 
1000 
 
% of Drug release =  Drug release  x 100 
Dose of Drug 
Dissolution studies were performed for all formulations. The mean values and 
standard deviations were calculated. 
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VIII) Determination of Assay and Related Substances.14 
 
1) Assay by HPLC: - 
Reagents: - 
• Acetonitrile : HPLC grade 
 
• Triethylamine : HPLC grade 
 
• Trifluroacetic acid : HPLC grade 
 
• Water : Water for injection 
 
Chromatographic condition: - 
 
Column  : Hypersil MOS1 C8 (250 x 4.6 mm, 5µ) 
Pump Mode : Isocratic 
Flow Rate : 0.9 ml/min 
 
Detection : UV, at 235 nm 
 
Column temperature : Ambient 
 
 
                               Injection volume                 : 20 µl 
 
                        Autosampler                     : 50C 
 
 
 
 
Preparation of Mobile Phase: - 
 
Add 450 ml of Acetonitrile to the 550 ml of Water and mix well. With 
condition stirring add 1ml of Triethylamine and 1ml of Trifluroacetic acid. 
Preparation of diluents 1: - 
 
Add 400 ml of Acetonitrile into 600 ml of water and mix well. 
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Preparation of Solution: - 
Sample Solution: - 
Weigh  about  quantity  of  the  powdered  tablets  equivalent  200  mg  of 
Gliclazide from 20 tablets into 50 ml of volumetric flask, and add 30 ml of 
Acetonitrile mix well and sonicate for 30 minutes and allow to cool at room 
temperature and make up  the volume with Acetonitrile and mix well. Filter 
the solution through nylon filter paper 0.45 µ and transfer this 5 ml to 100 
ml volumetric flask and make up the volume with Diluent  and mix well. 
Standard Solution: - 
 
Weigh about 40 mg of Gliclazide standard into 200 ml volumetric flask. 
Dissolve in 30 ml of Acetonitrile, sonicate for 5 minutes and make up the 
volume with Diluent and mix well. 
Evaluation of system suitability:- 
Inject 20 µl of Standard solution five times in to the chromatograph and 
measure the  Gliclazide peak areas. RSD for five replicates injections of 
standard solutions is not more than 2.0%. 
 
 
 
 
Procedure: - 
 
Inject  20µl  of  blank,  Standard  solution  and  sample  solution  into  the 
chromatograph, record the chromatograms. 
Calcualtion for tablets: - 
 
Content of Gliclazide  TA x DS x P x N 
(C15 H21 N3  O3  S) SA x DT  x 100 
mg per tablet 
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Where, 
 
TA = Average area counts of sample solution 
 
SA = Average area counts of  five replicate injection for Gliclazide peak in 
the chromatograms of standard solution. 
DS = Dilution factor of standard solution (weight / Dilution) 
DT = Dilution factor of sample solution (weight / Dilution) 
P = Percent purity of Gliclazide standard 
 
N = Average weight of the tablet. 
 
2)  Related substances: - 
Preparation of Diluent 1: - 
Add 450 ml of Acetonitrile into the 550 ml of water and mix well. 
 
Preparation of Diluent 2: - 
 
Add 300 ml of Acetonitrile into the 600 ml of water and mix well 
 
Preparation of sample solution: - 
Weigh  about  quantity  of  powdered  tablets  equivalent  200  mg  of 
Glicalzide (from 20 tablets) into 50 ml of volumetric flask, and add 30 ml of 
Acetonitrile mix well  and  sonicate it for 30 minutes allow cooling at room 
temperature and making up the  volume with Acetonitrile and mixing well. 
 
                      Filter the solution through nylon filter paper 0.45µ and transfer this 10 ml to 
50 ml volumetric flask and make up the volume with Diluent 2 and mix well. 
 
Placebo preparation: - 
Weigh about quantity of the 934 mg of placebo to 50 ml of 
volumetric flask, and add 30 ml of Acetonirile mix well and sonicate for 30 
minutes allow cooling at room temperature and making up the volume with  
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         Acetonirile and mixing well. Filter the solution through nylon filter paper           
0.45µ and transfer this 10 ml to 50 ml volumetric flask and make up the volume  
with Diluent 2 and mix well. 
Standard Solution: - 
 
Weigh  accurately  about  40  mg  of  Gliclazide  standard  into  200  ml 
volumetric  flask. Dissolve in 10 ml of Acetonitrile, and make up the volume with 
Diluent 1. Dilute 2 ml of this solution to 200 ml of volumetric flask and make up the 
volume with Diluent 1. 
Procedure: - 
 
Inject  20µl  of  blank,  placebo  standard  solution  and  sample  solution; 
 
measure peak response and calculate. 
 
Calculation: - 
 
Total impurities: AT1 x DC  x P x 100 x N 
AC  x DT x 100 x L 
Where, 
 
AT1 = Area count of Single maximum impurity peak in the chromatogram of sample 
AC  = Area count of Gliclazide peak in the chromatogram of standard solution 
DC  = Dilution factor for the standard solution (weight / dilution) 
DT = Dilution factor for the sample solution (weight / dilution) 
P = Percent potency of Gliclazide working standard used 
            N = Average weight of the tablets 
L = Lable claim of Gliclazide 
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IX) Data Analysis (Curve Fitting Analysis). 25, 34 
 
To analyze the mechanism of the drug release rate kinetics of the dosage form, 
the data obtained were graphed as: 
1)  Cumulative percentage drug released Vs Time (In-Vitro drug release plots) 
 
2)  Cumulative percentage drug released Vs Square root of time (Higuchi’s 
plots) 
3)  Log cumulative percentage drug remaining Vs Time (First order plots) 
 
4)  Log percentage drug released Vs Log time (Peppas plots) 
 
 
 
• Higuchi release model: - 
 
To study the Higuchi release kinetics, the release rate data were fitted 
to the following equation. 
F = K .t1/2 
 
Where, ‘F’ is the amount of drug release, 
 
‘K’ is the release rate constant, and 
 
‘t’ is the release time. 
 
When the data is plotted as accumulative drug released versus square root of 
time,  yields  a  straight  line,  indicating  that  the  drug  was  released  by  diffusion 
mechanism. The slope is equal to ‘K’. 
• Korsmeyer and Peppas release model: - 
The release rate data were fitted to the following equation, 
Mt  /M∞  = K. tn 
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Where, Mt  /M∞  is the fraction of drug release, 
 
‘K’ is the release constant, 
 
‘t’ is the release time, and 
 
‘n’ is the diffusional exponent for the drug release that 
is dependent on the shape of the matrix dosage form. 
When the data is plotted as Log of drug released versus Log time, yields a 
straight line with a slope equal to ‘n’ and the ‘K’ can be obtained from Y- intercept. 
For non-Fickian release the ‘n’ values falls between 0.5 and 1.0, while for 
 
Fickian (case I) diffusion n=0.5 and zero order release (case II transport) n=1.0. 
 
 
• Zero order release rate kinetics: - 
 
To study the zero–order release kinetics the release rate data are fitted to the 
following equation. 
F= Kt 
 
Where ‘F’ is the fraction of drug release, 
 
‘K’ is the release rate constant and 
 
‘t’ is the release time. 
 
When the data is plotted as cumulative percent drug release versus time, if the plot 
is linear then the data obeys zero-order release kinetics, with a slope equal to K. 
• First Order Kinetics: 
 
A first order release would be predicated by the following equation. 
 
 
 
 
Log C = log Co   – 
 
 
Kt 
 
 
 
2.30 
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Where; C = Amount of drug remained at 
time‘t’ Co = Initial amount of drug 
K = First order rate constant (hr-1) 
When the data is plotted as cumulative percent drug remaining versus time 
yields a  straight  line, indicating that the release follows First-order kinetics. The 
constant ‘k’ can be obtained by multiplying 2.303 with slope values. 
 
X) STABILITY STUDIES.89, 90 
 
1. Introduction: - 
In  any rational  drug design  or  evaluation  of dosage forms  for  drugs,  the 
stability of the  active component  must  be a major criterion  in  determining their 
acceptance or rejection. 
Stability of a drug can be defined as the time from the date of manufacture and the 
packaging of the formulation, until its chemical or biological activity is not less than a 
predetermined  level  of  labeled  potency  and  its  physical  characteristics  have  not 
changed appreciably or deleteriously. 
2. Objective of the Study. 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. 
Long-term Testing: 250  C ± 20  C / 60 % RH ± 5 % for 12 Months. 
Accelerated Testing: 400 C ± 20  C / 75 % RH ± 5 % for 6 Months. 
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The International Conference on Harmonization (ICH) Guidelines titled “Stability 
Testing  of  New  Drug  substance  and  Products”  (QIA)  describes  the  stability test 
requirements for drug registration applications in the European Union, Japan and the 
United States of America. 
ICH specifies the length of study and storage conditions. 
Stability studies were carried out at 250  C / 60 % RH and 400  C / 75 % RH for the 
selected formulation for the period of 3 months. 
Method: - 
 
The selected formulations were packed in amber-colored bottles, which were 
tightly plugged with cotton and capped. They were then stored at 250  C / 60% RH and 
400  C / 75 % RH for 3 months and evaluated for their physical appearance, drug 
 
content and drug excipients compatibility at specified intervals of time. 
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RESULTS & DISCUSSION 
 
I. CALIBRATION CURVE. 
 
 
Standard Calibration Curve of Gliclazide in phosphate buffer pH 7.4:- 
 
 
Standard calibration curve of Gliclazide was drawn by plotting absorbance v/s 
concentration.  The absorbance values are tabulated in Table 6. Standard calibration 
curve of Gliclazide in the Beer's range between 5-25 µg/ml is shown in Fig.11 
Table No. 7. Calibration data of Gliclazide in phosphate buffer pH 7.4 at 226 nm 
and 290 nm. 
 
 
SL. 
No. 
Concentration 
(µg/ml) 
 
Absorbance* 
1 0 0 
2 5 0.108 
3 10 0.224 
4 15 0.339 
5 20 0.423 
6 25 0.552 
*Average of 3 determinations 
 
 
The linear regression analysis for standard curve in phosphate buffer pH 7.4:- 
 
The linear regression analysis was done on absorbance data points. The 
results are as follows: 
The Slope = 0.022 
 
The intercept = 0 .002 
 
The correlation coefficient = 0.996 
 
A straight-line equation (y = mx + c) was generated to facilitate the calculation for 
amount of drug. The equation is as follows. 
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Fig.11: Standard calibration curve for Gliclazide in phosphate buffer pH 7.4 at 
226 nm and 290 nm. 
 
Absorbance = 0.022 x Concentration 
 
 
 
 
II COMPATIBILITY STUDY:- 
 
Compatibility studies were performed using IR spectrophotometer. The IR 
spectrum of pure drug and physical mixture of drug and polymer were studied making 
a  KBr  disc.  The  characteristic  absorption  peaks  of  Gliclazide  were  obtained  at 
different wave numbers in different samples. 
The peaks obtained in the spectra of each formulation correlates with the peaks of 
drug  spectrum.  This  indicates  that  the  drug  is  compatible  with  the  formulation 
components. The spectra for all formulations are shown below. 
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The spectral details for all types of formulations are shown as follows 
 
 
 
Table no 8- FTIR  values in Pure drug Gliclazide. 
 
 
IR Spectrum 
S.No (KBr Disc) peaks at Indications 
1. 3272 cm-1 NH, str. 
2. 3118 cm-1 CH, str Ar 
3. 2931 cm-1 CH str. CH3 
4. 1708 cm-1 C=O str. 
5. 1438,1352 cm-1 C=C str. 
6. 1163 cm-1 C-N str 
 
 
 
 
Table no 9- FTIR  values in  Gliclazide + HPC 75-100 
 
 
IR Spectrum 
S.No (KBr Disc) peaks at Indications 
1. 3771 - 3190 cm-1 NH, str. 
2. 2939 cm-1 CH, str. CH3 
3. 1708 cm-1 C=C, str, 
4. 1436, 1348 cm-1 C=C, str 
5. 1160, cm-1 C- N str 
 
 
 
 Table no 10 - FTIR  values in Gliclazide + HPMC 
 
 
IR Spectrum 
S.No (KBr Disc) peaks at Indications 
1. 3272 cm-1 NH, str 
2. 3116 cm-1 CH, st. Ar 
3. 2935 cm-1 CH str, CH3 
4. 1708 cm-1 C=O, str 
5. 1596, 1436 cm-1 C=C str 
6. 1163 cm-1 C-N str 
 
 
 
 
 
 Chapter-VI Results & Discussion 
 
 
 
 
 
 
Fig. No-12: IR Spectrum of Gliclazide Pure Drug 
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Fig.No-13: IR Spectrum of Gliclazide + HPMC K4M 
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Fig. No-14: IR Spectrum of Gliclazide + HPC 75-100 
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Table No. 11: Physical Properties of all granules 
 
 
 
 
Formulations Angle of repose (θ) 
Compressibility Index or 
Carr’s Index (%) 
 
Hausner’s ratio Drug uniformity* (%) 
F1 280.95′ 15.15 1.178 98.94±0.40 
F2 290.56′ 15.38 1.182 97.31±0.32 
F3 250.94′ 16.42 1.196 99.75±0.33 
F4 230.96′ 16.92 1.204 96.31±0.41 
F5 240.14′ 16.42 1.196 98.69±0.22 
F6 250.91′ 16.67 1.2 99.75±0.34 
F7 220.69′ 14.28 1.167 99.75±0.21 
F8 230.58′ 16.67 1.2 98.94±0.25 
F9 250.λ5′ 14.92 1.175 99.75±0.34 
*mean±SD, n=3. 
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V. Table No. 12: Physical Properties of all Formulations. 
 
 
Formulations Diameter* (mm) 
Thickness* 
(mm) 
# Weight variation
 
(mg) 
Hardness* 
(kg /cm2) 
 
Friability (%) 
 
Drug content* (%) 
F1 10.05±0.030 4.45±0.11 351±5 5.1 ± 0.12 0.191 97.00±0.24 
F2 10.06±0.040 4.50±0.04 350±5 5.5 ± 0.24 0.290 98.90±0.22 
F3 10.04±0.030 4.49±0.05 354±5 5.8 ± 0.21 0.146 97.86±0.34 
F4 10.02±0.030 4.45±0.12 345±5 5 .2± 0.23 0.149 98.75±0.32 
F5 10.02±0.054 4.46±0.03 347±5 5.9 ± 0.12 0.145 96.26±0.46 
F6 10.05±0.064 4.54±0.23 351±5 6.1 ± 0.14 0.191 98.45±0.26 
F7 10.07±0.022 4.52 ±0.2 352±5 5.2 ± 0.18 0.193 98.00±0.28 
F8 10.05±0.035 4.51±0.12 349±5 5.4 ± 0.22 0.146 99.72±0.30 
F9 10.04±0.059 4.53 ±0.3 348±5 6 .1± 0.21 0.191 98.82±0.34 
* mean ±SD, n=6. # mean ±SD, n=20. 
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III. EVALUATION OF PRE-COMPRESSION PARAMETER. 
 
1. Pre-compression Parameters. 
 
1) Angle of repose (θ): - 
 
The values  obtained  for  angle  of  repose  for  all  (F1 -F9 ) formulations  are tabulated  
in  Table.6.  The  values  were  found  to  be  in  the  range  from  220.69′  - 
290.56’.This indicates good flow property of the granules. 
 
2) Compressibility index: - 
 
 
The values obtained for compressibility index for all (F1 -F9 ) formulations are tabulated 
in Table.6. Compressibility index value ranges between 14.28% - 16.92% 
indicating that the granules have the required flow property for compression. 
 
 
3) Hausner’s ratio: - 
 
The values obtained for hausner’s ratio for all (F1 -F9 ) formulations are in 
Table.6. Hausner’s ratio value ranges between 1.167 - 1.2 indicating that the granules have the 
required flow property for compression. 
 
 
4) Drug uniformity: - 
 
 
The percentage of drug uniformity was found to be between 96.31 % - 99.75 
% of Gliclazide, which was within acceptable limits. Table.6. showed the results of drug 
content uniformity in each batch. 
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2. Post-compression Parameters. 
 
1) Shape of the tablet: - 
 
Microscopic  examination  of  tablets  from  each  formulation  batch  showed circular 
shape with no cracks. 
 
2) Tablet dimensions: - 
 
The dimensions determined for formulated tablets were tabulated in Table.7. Tablets 
mean thicknesses were almost uniform in all the formulations and were found to be in the range 
of 4.45 mm – 4.54 mm. The diameter of the tablet ranges between 
10.02 mm – 10.07 mm. 
 
 
 
3) Weight variation Test: - 
 
 
The percentage weight variation for all formulations was shown in Table.7. All the 
tablets passed weight variation test as the % weight variation was within the Pharmacopoeial 
limits. The weights of all the tablets were found to be uniform with low standard deviation 
values 
 
4) Hardness test: - 
The measured hardness of tablets of each batch was in Table.7 and it was range 
between 5.1 kg/cm2  - 6.1 kg/cm2. Tablet hardness was increased as increasing the compression 
force. This ensures good handling characteristics of all batches. 
 
 
5) Friability test: - 
 
The values of friability test were tabulated in Table.7. The % friability was 
 
NMT 1% in all the formulations ensuring that the tablets were mechanically stable. 
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6) Drug content: - 
 
 
The percentage of drug content was found to be between 97.00 % - 99.72 % of 
Gliclazide, which was within acceptable limits. Table no.7 showed the results of drug content 
uniformity in each batch. 
 
7) Swelling index: - 
 
 
 
Swelling index of all formulations is shown in table no.8 and Fig no.18, 19 & 
20 as time increases the swelling index was increased, because weight gained by tablet was 
increased proportionally with the rate of hydration up to 3 hours, 4 hours for HPMC and HPC 
respectively. Later on it decreases gradually due to dissolution of outermost gelled layer of 
tablet into dissolution medium. The direct relationship was observed between 
Swellin indexand polymer concentration, as polymer concentration increases, swelling index  
was increased. Comparison between HPMC and HPC. It has been observed that swelling  
index  is more in HPMC followed by HPC.  It  was  observed  that  cumulative  %  drug  
release  decrease  with  increasing concentration of polymer and swelling index. 
Table. No .13: Swelling Index Behavior Study of selected Formulations* 
 
 
 
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 12.5 15.45 17.56 27.2 39.2 48.32 14.3 31.21 42.76 
2 18.3 22.34 24.34 42.6 61.34 72.21 20.09 41.4 55.34 
3 21.78 27.14 30.4 55.2 77.34 93.32 28.34 53.8 65.76 
4 23.34 31.98 36.87 53.2 75.03 87.23 35.67 65.5 79.3 
5 27.34 36.45 41.34 49.2 65.03 83.32 33.21 63.3 77.9 
6 29.56 38.67 48.14 45.01 59 79.24 29.4 57.6 72.4 
7 25.23 33.4 45.87 33.01 54.02 68.21 27.23 53.4 63.45 
8 19.9 28.3 41.76 25.03 48.23 62.1 26.34 48.43 57.98 
9 16.45 25.9 38.56 19.14 42.21 54.21 24.8 39.23 51.23 
10 13.6 19.34 32.4 15.09 33.8 47.28 23.8 36.45 42.8 
11 10.34 14.34 26.5 14.06 24.27 41.09 20.35 32.2 34.54 
12 8.45 11.1 22.8 12.08 19.2 37.4 19.23 27.4 31.4 
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Fig no-15 Swelling Index of  Formulations F1,F2 and F3 
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Fig no.16 Swelling Index of  Formulations F4,F5 and F6 
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Fig no.17 Swelling Index of  Formulations F7,F8 and F9 
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Table No. 14: In vitro drug release profile of Gliclazide from F1  Formulation: - (HPC K4 M) 
 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.058 2.636 11.863 19.772 1.296 88.136 1.945 
2 1.414 0.301 0.124 5.636 25.363 42.272 1.626 74.636 1.872 
3 1.732 0.477 0.18 8.181 36.818 61.363 1.787 63.181 1.800 
4 2 0.602 0.243 11.045 49.704 82.840 1.918 50.295 1.701 
6 2.449 0.778 0.287 13.045 58.704 97.840 1.990 41.295 1.615 
*Each reading is an average of three determinations 
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Table No. 15: In vitro drug release profile of Gliclazide from F2 Formulation: - HPC 75-100 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.044 2 9 15 1.176 91 1.959 
2 1.414 0.301 0.078 3.545 15.954 26.590 1.424 84.045 1.924 
3 1.732 0.477 0.125 5.681 25.568 42.613 1.629 74.431 1.871 
4 2 0.602 0.179 8.136 36.613 61.022 1.785 63.386 1.801 
6 2.449 0.778 0.243 11.045 49.704 82.840 1.918 50.295 1.701 
8 2.828 0.903 0.289 13.136 59.113 98.522 1.993 40.886 1.611 
*Each reading is an average of three determinations. 
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Table No. 16: In vitro drug release profile of Gliclazide from F3 Formulation: - HPC 75-100 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.048 2.181 9.818 16.363 1.213 90.181 1.955 
2 1.414 0.301 0.084 3.818 17.181 28.636 1.456 82.818 1.918 
3 1.732 0.477 0.118 5.363 24.136 40.227 1.604 75.863 1.880 
4 2 0.602 0.158 7.181 32.318 53.863 1.731 67.681 1.830 
6 2.449 0.778 0.215 9.772 43.977 73.295 1.865 56.022 1.748 
8 2.828 0.903 0.251 11.409 51.340 85.568 1.932 48.659 1.687 
10 3.162 1 0.288 13.090 58.909 98.181 1.992 41.090 1.613 
*Each reading is an average of three determinations 
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                     Figure – 18 In-vitro drug release profile for F1, F2, and F3formulations 
 
  
   
 
 
Figure – 19 First order drug release plots F1, F2, and F3 formulations 
 82 
Chapter-VI Result & Discussion 
 
 
 
 
 
 
 
 
 
 
Figure – 20 Higuchi plots for F1, F2, and F3 formulations 
 
 
 
 
 
 
 
Figure – 21 Peppas double log plots for F1, F2, and F3 formulations 
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Table No. 17: In vitro drug release profile of Gliclazide from F4 Formulation: - HPMC K-4 M 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.06 2.727 12.272 20.454 1.310 87.727 1.943 
2 1.414 0.301 0.131 5.954 26.795 44.659 1.649 73.204 1.864 
3 1.732 0.477 0.194 8.818 39.681 66.136 1.820 60.318 1.780 
4 2 0.602 0.242 11 49.5 82.5 1.916 50.5 1.703 
6 2.449 0.778 0.291 13.227 59.522 99.204 1.996 40.477 1.607 
*Each reading is an average of three determinations 
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Table No. 18: In vitro drug release profile of Gliclazide from F5 Formulation: - HPMC K-4 M 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.054 2.454 11.045 18.409 1.265 88.954 1.949 
2 1.414 0.301 0.094 4.272 19.227 32.045 1.505 80.772 1.907 
3 1.732 0.477 0.123 5.590 25.159 41.931 1.622 74.840 1.874 
4 2 0.602 0.162 7.363 33.136 55.227 1.742 66.863 1.825 
6 2.449 0.778 0.201 9.136 41.113 68.522 1.835 58.886 1.770 
8 2.828 0.903 0.243 11.045 49.704 82.840 1.918 50.295 1.701 
10 3.162 1 0.287 13.045 58.704 97.840 1.990 41.295 1.615 
*Each reading is an average of three determinations 
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Table No. 19: In vitro drug release profile of Gliclazide from F6  Formulation: - HPMC K-4 M 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.037 1.681 7.568 12.613 1.100 92.431 1.965 
2 1.414 0.301 0.069 3.136 14.113 23.522 1.371 85.886 1.933 
3 1.732 0.477 0.097 4.409 19.840 33.068 1.519 80.159 1.903 
4 2 0.602 0.133 6.045 27.204 45.340 1.656 72.795 1.862 
6 2.449 0.778 0.179 8.136 36.613 61.022 1.785 63.38 1.801 
8 2.828 0.903 0.236 10.727 48.272 80.454 1.905 51.727 1.713 
10 3.162 1 0.259 11.772 52.977 88.295 1.945 47.022 1.672 
12 3.464 1.079 0.288 13.090 58.909 98.181 1.992 41.090 1.613 
*Each reading is an average of three determinations 
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                       Figure – 22 In-vitro drug release profile for F4, F5, and F6 formulations 
 
 
 
 
 
 
 
               Figure – 23 First order drug release plots for  F4, F5, and F6  formulations 
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Figure – 24 Higuchi plots for   F4, F5, and F6 formulations 
 
 
 
 
 
 
 
Figure – 25 Peppas double log plots for F4, F5, and F6 formulations 
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Table No. 20: In vitro drug release profile of Gliclazide from F7  Formulation: - HPMC K-4 M + HPC 75-100 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.049 2.227 10.022 16.704 1.222 89.977 1.954 
2 1.414 0.301 0.093 4.227 19.022 31.704 1.501 80.977 1.908 
3 1.7320 0.477 0.141 6.409 28.840 48.068 1.681 71.159 1.852 
4 2 0.602 0.182 8.272 37.227 62.045 1.792 62.772 1.797 
6 2.449 0.778 0.246 11.181 50.318 83.863 1.923 49.681 1.696 
8 2.828 0.903 0.288 13.090 58.909 98.181 1.992 41.090 1.613 
*Each reading is an average of three determinations 
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Table No. 21: In vitro drug release profile of Gliclazide from F8  Formulation: - HPMC K-4 M + HPC 75-100 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.044 2 9 15 1.176 91 1.959 
2 1.414 0.301 0.084 3.818 17.181 28.636 1.456 82.818 1.918 
3 1.732 0.477 0.112 5.090 22.909 38.181 1.581 77.090 1.887 
4 2 0.602 0.144 6.545 29.454 49.090 1.691 70.545 1.848 
6 2.449 0.778 0.189 8.590 38.659 64.431 1.809 61.340 1.787 
8 2.828 0.903 0.245 11.136 50.113 83.522 1.921 49.886 1.697 
10 3.162 1 0.287 13.045 58.704 97.840 1.990 41.295 1.615 
*Each reading is an average of three determinations 
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Table No. 22: In vitro drug release profile of Gliclazide from F9  Formulation: - HPMC K-4 M + HPC 75-100 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.036 1.636 7.363 12.272 1.088 92.636 1.966 
2 1.414 0.301 0.066 3 13.5 22.5 1.352 86.5 1.937 
3 1.732 0.477 0.092 4.181 18.818 31.363 1.496 81.181 1.909 
4 2 0.602 0.138 6.272 28.227 47.045 1.672 71.772 1.855 
6 2.449 0.778 0.183 8.318 37.431 62.386 1.795 62.568 1.796 
8 2.828 0.903 0.235 10.681 48.068 80.113 1.903 51.931 1.715 
10 3.162 1 0.264 12 54 90 1.954 46 1.662 
12 3.464 1.079 0.291 13.227 59.522 99.204 1.996 40.477 1.607 
*Each reading is an average of three determinations 
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Table No. 23: In vitro drug release profile of Gliclazide from Diamicron Formulation: - 
 
 
 
 
Time 
(hrs) 
 
√T 
 
Log T 
 
Abs* 
 
Conc. 
(µg/ml) 
 
CDR 
(mg) 
 
CDR (%) 
 
Log % CDR 
 
Cumulative % 
drug remained 
Cumulative 
Log % Drug 
remained 
0 0 0 0 0 0 0 0 100 2 
1 1 0 0.036 1.636 7.363 12.272 1.088 92.636 1.966 
2 1.414 0.301 0.069 3.136 14.113 23.522 1.371 85.886 1.933 
3 1.732 0.477 0.098 4.454 20.045 33.409 1.523 79.954 1.902 
4 2 0.602 0.138 6.272 28.227 47.045 1.672 71.772 1.855 
6 2.449 0.778 0.19 8.636 38.863 64.772 1.811 61.136 1.786 
8 2.828 0.903 0.236 10.727 48.272 80.454 1.905 51.727 1.713 
10 3.162 1 0.26 11.818 53.181 88.636 1.947 46.818 1.670 
12 3.464 1.079 0.289 13.136 59.113 98.522 1.993 40.886 1.611 
*Each reading is an average of three determinations. 
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Figure – 26  In-vitro drug release profile for F7, F8, and F9 formulations 
 
 
 
 
 
 
 
 
 
 
                       Figure – 27 First order drug release plots for   F7, F8, and F9 formulations 
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              Figure – 28 Higuchi plots for F7, F8, and F9 formulations 
 
 
 
 
 
 
 
 
 
                   Figure – 29 Peppas double log plots for  F7, F8, and F9 formulations 
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Table No. 24: In vitro drug release for all tablets formulation 
 
 
 
 
TIME 
(Hrs) 
 
FORMULATIONS 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
Diamicron 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1 
 
19.772 
 
15 
 
16.363 
 
20.454 
 
18.409 
 
12.613 
 
16.704 
 
15 
 
12.272 
 
12.272 
 
2 
 
42.272 
 
26.590 
 
28.636 
 
44.659 
 
32.045 
 
23.522 
 
31.704 
 
28.636 
 
22.5 
 
23.522 
 
3 
 
61.363 
 
42.613 
 
40.227 
 
66.136 
 
41.931 
 
33.068 
 
48.068 
 
38.181 
 
31.363 
 
33.409 
 
4 
 
82.840 
 
61.022 
 
53.863 
 
82.5 
 
55.227 
 
45.340 
 
62.045 
 
49.090 
 
47.045 
 
47.045 
 
6 
 
97.840 
 
82.840 
 
73.295 
 
99.204 
 
68.522 
 
61.022 
 
83.863 
 
64.431 
 
62.386 
 
64.772 
 
8  
 
98.522 
 
85.568  
 
82.840 
 
80.454 
 
98.181 
 
83.522 
 
80.113 
 
80.454 
 
10   
 
98.181  
 
97.840 
 
88.295  
 
97.840 
 
90 
 
88.636 
 
12      
 
98.181   
 
99.204 
 
98.522 
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Table No. 25: Curve fitting data for all tablet formulations 
 
 
 
FORMULATION 
 
ZERO ORDER FIRST ORDER 
 
HIGUCHI 
 
PEPPAS 
 
 
Slope (K) 
 
R2 
 
Slope 
 
(K) 
 
R2 Slope (K) 
 
R2 
 
Slope (n) 
 
R2 
F1 16.96 0.964 -0.067 -0.1543 0.987 55.965 0.985 0.919 0.980 
F2 12.69 0.985 -0.050 -0.1152 0.995 48.145 0.989 0.943 0.991 
F3 9.734 0.973 -0.039 -0.0898 0.997 39.075 0.996 0.794 0.995 
F4 17.09 0.958 -0.068 -0.1566 0.989 55.755 0.988 0.902 0.974 
F5 9.298 0.969 -0.037 -0.0852 0.995 36.479 0.997 0.717 0.996 
F6 8.276 0.976 -0.033 -0.076 0.995 36.379 0.994 0.841 0.995 
F7 12.43 0.978 -0.049 -0.1128 0.998 46.079 0.997 0.869 0.993 
F8 9.536 0.987 -0.037 -0.0852 0.997 38.372 0.994 0.804 0.998 
F9 8.433 0.976 -0.033 -0.076 0.996 37.25 0.993 0.865 0.992 
Diamicron 8.320 0.971 -0.033 -0.076 0.995 36.617 0.995 0.852 0.991 
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Table No .26: Assay and Releated substances in the F6, F9 & Diamicron 
Formulations 
 
 
 
 
Formulations 
 
Assay 
 
Related Substances 
 
F6 
 
98.90% 
 
0.53% 
 
F9 
 
98.67% 
 
0.44% 
 
Diamicron 
 
99.01% 
 
0.58% 
*Each reading is an average of three determinations. 
 
 
 
 
Table No 27: Stability data of F6 formulation 
 
 
Time in 
months 
 
Formulation F6 stored at 400C/ 75% RH 
Physical appearance % Drug content 
1 +++ 98.76 
2 +++ 98.38 
3 ++ 97.98 
+++ = Same as on zero day, ++ = Slight change in color 
 
 
 
 
 
 
 
Table No 28: Stability data of F9 formulation 
 
 
Time in 
months 
 
Formulation F9 stored at 400C/ 75% RH 
Physical appearance % Drug content 
1 +++ 98.45 
2 +++ 99.76 
3 ++ 98.89 
+++ = Same as on zero day, ++ = Slight change in color 
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VI) In-vitro Dissolution Study. 
 
The in-vitro drug release of the entire matrix tablets were carried in phosphate 
buffer pH 7.4 from 0 to 12 hrs by USP XXIV type-II apparatus and the values are 
shown in Table no. 10 to 18. The plot of % Cumulative drug release v/s time (hrs) 
was plotted and depicted as shown in Fig no18 and 22. 
From the in-vitro dissolution data, it was found that the drug release from 
marketed sample Diamicron XR containing gliclazide is 98.52% in 12 hrs, Hydroxy 
propyl cellulose 24%  (F1)  97.84 % in 6 hrs, Hydroxy propyl cellulose 28% (F2) 
98.52% in 08 hrs, Hydroxy propyl cellulose 32% (F3) 98.18% in 10 hrs. Hydroxy 
propyl methyl cellulose 24% (F4 ) 99.20% in 06 hrs, Hydroxy propyl methyl cellulose 
28% (F5 ) 97.84% in 10 hrs, Hydroxy propyl methyl cellulose 32% (F6) 98.18% in 12 
hrs,  where  as  in  case  of  Hydroxy  propyl  methyl  cellulose  and  Hydroxy  propyl 
cellulose combination 24 % (F7) 98.18% in 08 hrs, Hydroxy propyl methyl cellulose 
and Hydroxy propyl cellulose combination 28% (F8) 97.84% in 10 hrs and Hydroxy 
propyl methyl cellulose and Hydroxy propyl cellulose combination 32% (F9) 99.20% 
in 12 hrs. 
 
From the results it was observed that increasing the amount of polymer in the 
formulations, resulted in slower rate and decreased amount of drug release from the 
tablet.  Comparison  between   Hydroxy  propyl  cellulose,  Hydroxy  propyl  methyl 
cellulose and combination of Hydroxy propyl  cellulose and Hydroxy propyl methyl 
cellulose based tablets, release of drug from Hydroxy propyl  cellulose based tablet 
was found to be more faster compared to Hydroxy propyl cellulose and  Hydroxy 
propyl methyl cellulose based tablet. The maximum drug release was found to be 
98.18% over a period of 12 hours in Hydroxy propyl methyl cellulose based tablets 
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(F6 ). Similarly maximum drug release was found to be 99.20% over a period of 
12hours in Hydroxy propyl cellulose and Hydroxy propyl methyl cellulose based 
tablets (F9 ).  This  indicates  that  the minimum  quantity of Hydroxy propyl  
cellulose and maximum quantity of Hydroxy propyl methyl cellulose required to 
prepare the sustain 
release matrix tablets of Gliclazide. 
 
Order of retardation of different formulation is in the following sequence 
 
Hydroxy propyl methyl cellulose > Hydroxy propyl cellulose . 
 
VII) Curve Fitting Analysis. 
Table no.20 shows data analysis of release profiles according to different 
kinetics models. The kinetic treatment reflected that release data of Hydroxy propyl 
cellulose formulation that is F1, F2 & F3 showed higher  r2  values for first order plot 
indicating that release of drug  follows first order kinetic, further Korsmeyer and 
peppas equation resulted into the value of n in the range of 0.980 to 0.995  with all the 
tablets indicating a non-fickian diffusion  mechanism and may indicate that the drug 
release is controlled by more than one process. 
 
The kinetic treatment reflected that release data of Hydroxy propyl methyl cellulose 
formulation that is F4, F5 & F6 showed higher  r2  values for First order plot indicating 
that release of drug follows first order kinetic, further Korsmeyer and peppas equation 
resulted  into  the  value  of  n  in  the  range  of  0.974  to  0.996  with  all  the  tablets 
indicating a non-fickian diffusion  mechanism and may indicate that the drug release 
is controlled by more than one process. 
 
The kinetic treatment reflected that release data of Hydroxy propyl methyl cellulose 
and Hydroxy propyl cellulose combination formulation that is F7, F8 & F9 showed  
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higher  r2 values for first order plot indicating that release of drug follows first order 
kinetic, further Korsmeyer and peppas equation resulted into the value of n of n in the 
range  of  0.992  to  0.998  with  all  the  tablets  indicating  a  non-fickian  diffusion 
mechanism and may indicate that the drug release is controlled by more than one 
process. 
IX) Stability Studies. 
The selected Formulation  F6 & F9 were evaluated for stability studies which were 
stored at 400C  at 75% RH tested for 3 months and were analyzed for their drug 
content at the monthly interval.  The residual drug contents of formulations were 
found to be within the permissible limits and the  results of 3 months duration are 
shown  in  the  Table  no  21  &  22  which  was  estimated  by  seeing  drug  content 
uniformity. 
 
 
In present investigation an attempt has been made to design and develop  some  
Gliclazide  matrix  tablets  using  Hydroxy  propyl  cellulose, Hydroxy propyl 
methyl  cellulose and their combination as release retarding polymers. Gliclazide  is 
oral hypoglycaemic drug which lowers blood glucose level and has been selected to 
prepare sustained release dosage forms. 
1.  Gliclazide sustained release matrix tablet were prepared using Hydorxy Propyl 
Cellulose,  Hydroxy Propyl Methyl Cellulose and their combination as base 
polymer by wet granulation method. 
2.  FT-IR spectral analysis showed that characteristic peak of Gliclazide pure drug 
was retained in the spectra of all the formulations indicating the inactness of the 
drug in all the formulations. 
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3.  The prepared tablets were evaluated for number of parameters like thickness, 
diameter, weight variation, swelling index and in vitro release studies. 
4.  All the prepared tablets were of smooth surface and elegant texture. 
 
5.  The  tablets  prepared  were  checked  visually  for  its  appearance  &  surface 
texture. 
6.  The weights of the tablets were in the range of 250 ± 5 mg. The thickness of 
the tablet was in the range of 4.45 ± 0.11 to 4.51 ± 0.12 mm. 
As the time increases, the swelling index was increased; later on it 
decreases gradually due to dissolution of outermost –gelled layer of tablet into 
dissolution  medium.  Comparison  between  Hydroxy  Propyl  Cellulose  and 
Hydroxy Propyl Methyl Cellulose, It has been observed that swelling index is  
               more in Hydroxy Propyl Methyl Cellulose. Drug  content uniformity study 
 
 
showed uniform dispersion of the drug throughout the formulation in the range 
of 97.00 ±0.24 to 99.72 ±0.30 %. 
7.  The maximum drug release was found to be 98.18% over a period of 12 hours 
in HPMC K4M based tablets (F6 ). Similarly maximum drug release was found 
to be 99.20% over a period of 12 hours in HPC 75-100 & HPMC K4M based 
tablets (F9 ) and maximum drug release was found to be 98.52% over a period 
of  12  hours  in  marketed  formulation  Diamicron.  This  indicates  that  the 
minimum quantity of HPC 75-100 and maximum quantity of HPMC required 
to prepare the sustain release matrix tablets of Gliclazide. 
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8.  The formulations were also subjected to model fitting analysis to know the 
order and  mechanism of drug release from the formulations by treating the data 
according to zero – order,  first – order, Higuchi and peppas equations. The 
data clearly shows that, the release kinetics revealed that the formulations 
containing HPMC K4M follows first – order drug  release with non-fickian 
diffusion, formulation containing HPC 75-100 & HPMC K4M follows first – 
order  drug  release  with  non-fickian  diffusion  and  the  marketed  sample 
Diamicron follows first – order drug release with non-fickian diffusion. 
 
9.  Stability studies reveled that there were no significant changes in physical 
properties and  drug contain of formulation F6 & F9 thus formulation were 
stable. 
10. It  can  be  concluded  that  Hydroxy  Propyl  Cellulose  and  Hydroxy  Propyl 
Methyl   Cellulose   combination   and   individual   Hydroxy  Propyl   Methyl 
Cellulose respectively can be used as an effective matrix former to sustain the 
release of Gliclazide for an extended period of 12 hrs. 
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In present investigation an attempt has been made to design and develop 
some  Gliclazide matrix tablets using Hydroxy propyl cellulose, Hydroxy propyl 
methyl cellulose and their combination as release retarding polymers.  
 
Gliclazide is  oral  hypoglycaemic  drug  which  lowers  blood  glucose  level  
and  has  been selected to prepare sustained release dosage forms. 
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